

DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG  
CI CM GA GN GW ML MR NE SN TD TG  
APPLICATION INFO.: WO 2000-AU1068 A 20000908  
PRIORITY INFO.: AU 1999-PQ 2726 19990909

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	28.54	28.75

STN INTERNATIONAL LOGOFF AT 12:08:57 ON 16 AUG 2006

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1642BJF

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	SEP 01	New pricing for the Save Answers for SciFinder Wizard within STN Express with Discover!
NEWS	4	OCT 28	KOREAPAT now available on STN
NEWS	5	NOV 30	PHAR reloaded with additional data
NEWS	6	DEC 01	LISA now available on STN
NEWS	7	DEC 09	12 databases to be removed from STN on December 31, 2004
NEWS	8	DEC 15	MEDLINE update schedule for December 2004
NEWS	9	DEC 17	ELCOM reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	10	DEC 17	COMPUAB reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	11	DEC 17	SOLIDSTATE reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	12	DEC 17	CERAB reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	13	DEC 17	THREE NEW FIELDS ADDED TO IFIPAT/IFIUDB/IFICDB
NEWS	14	DEC 30	EPFULL: New patent full text database to be available on STN
NEWS	15	DEC 30	CAPLUS - PATENT COVERAGE EXPANDED
NEWS	16	JAN 03	No connect-hour charges in EPFULL during January and February 2005
NEWS	17	FEB 25	CA/CAPLUS - Russian Agency for Patents and Trademarks (ROSPATENT) added to list of core patent offices covered
NEWS	18	FEB 10	STN Patent Forums to be held in March 2005
NEWS	19	FEB 16	STN User Update to be held in conjunction with the 229th ACS National Meeting on March 13, 2005
NEWS	20	FEB 28	PATDPAFULL - New display fields provide for legal status data from INPADOC
NEWS	21	FEB 28	BABS - Current-awareness alerts (SDIs) available
NEWS	22	FEB 28	MEDLINE/LMEDLINE reloaded
NEWS	23	MAR 02	GBFULL: New full-text patent database on STN
NEWS	24	MAR 03	REGISTRY/ZREGISTRY - Sequence annotations enhanced
NEWS	25	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS EXPRESS			JANUARY 10 CURRENT WINDOWS VERSION IS V7.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 10 JANUARY 2005
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS INTER			General Internet Information
NEWS LOGIN			Welcome Banner and News Items
NEWS PHONE			Direct Dial and Telecommunication Network Access to STN
NEWS WWW			CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 12:53:49 ON 16 MAR 2005

=> file medline

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'MEDLINE' ENTERED AT 12:54:02 ON 16 MAR 2005

FILE LAST UPDATED: 15 MAR 2005 (20050315/UP). FILE COVERS 1950 TO DATE.

On December 19, 2004, the 2005 MeSH terms were loaded.

The MEDLINE reload for 2005 is now available. For details enter HELP RLOAD at an arrow prompt (=>). See also:

<http://www.nlm.nih.gov/mesh/>

[http://www.nlm.nih.gov/pubs/techbull/nd04/nd04\\_mesh.html](http://www.nlm.nih.gov/pubs/techbull/nd04/nd04_mesh.html)

OLDMEDLINE now back to 1950.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2005 vocabulary.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s phosphol? or phosphatidyl?

110488 PHOSPHOL?

74227 PHOSPHATIDYL?

L1 151259 PHOSPHOL? OR PHOSPHATIDYL?

=> s antibod?

L2 682382 ANTIBOD?

=> s cancer? or tumor? or neoplas?

516585 CANCER?

722125 TUMOR?

1408989 NEOPLAS?

L3 1694388 CANCER? OR TUMOR? OR NEOPLAS?

=> s l1 and l2

L4 11100 L1 AND L2

=> s l3 and l4

L5 1564 L3 AND L4

=> s l1/ab

76652 PHOSPHOL?/AB

46123 PHOSPHATIDYL?/AB

L6 101821 (PHOSPHOL?/AB OR PHOSPHATIDYL?/AB)

=> s phospholipid? or phosphatidyl?

79525 PHOSPHOLIPID?

74227 PHOSPHATIDYL?

L7 128238 PHOSPHOLIPID? OR PHOSPHATIDYL?

=> s 17/ab  
51765 PHOSPHOLIPID?/AB  
46123 PHOSPHATIDYL?/AB  
L8 82550 (PHOSPHOLIPID?/AB OR PHOSPHATIDYL?/AB)

=> s 18 (s) 12  
L9 2063 L8 (S) L2

=> s 19 and 13  
L10 168 L9 AND L3

=> s 110 not py>1998  
3260901 PY>1998  
L11 111 L10 NOT PY>1998

=> s 111 and vascula?  
368610 VASCULA?  
L12 4 L11 AND VASCULA?

=> d ibib 1-4

L12 ANSWER 1 OF 4 MEDLINE on STN  
ACCESSION NUMBER: 1999002666 MEDLINE  
DOCUMENT NUMBER: PubMed ID: 9788617  
TITLE: Infarction of solid Hodgkin's tumors in mice by antibody-directed targeting of tissue factor to tumor vasculature.  
AUTHOR: Ran S; Gao B; Duffy S; Watkins L; Rote N; Thorpe P E  
CORPORATE SOURCE: Hamon Center for Therapeutic Oncology Research and the Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas 75235, USA.  
CONTRACT NUMBER: 1R01CA74951-01 (NCI)  
5R01CA54168-05 (NCI)  
SOURCE: Cancer research, (1998 Oct 15) 58 (20) 4646-53.  
Journal code: 2984705R. ISSN: 0008-5472.  
PUB. COUNTRY: United States  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 199811  
ENTRY DATE: Entered STN: 19990106  
Last Updated on STN: 19990106  
Entered Medline: 19981106

L12 ANSWER 2 OF 4 MEDLINE on STN  
ACCESSION NUMBER: 97234011 MEDLINE  
DOCUMENT NUMBER: PubMed ID: 9118509  
TITLE: Coexistence of anti-phospholipid antibodies and endothelial perturbation in systemic lupus erythematosus patients with ongoing prothrombotic state.  
AUTHOR: Ferro D; Pittoni V; Quintarelli C; Basili S; Saliola M; Caroselli C; Valesini G; Violi F  
CORPORATE SOURCE: Istituto di I Clinica Medica, Universita La Sapienza, Rome, Italy.  
SOURCE: Circulation, (1997 Mar 18) 95 (6) 1425-32.  
Journal code: 0147763. ISSN: 0009-7322.  
PUB. COUNTRY: United States  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals  
ENTRY MONTH: 199704  
ENTRY DATE: Entered STN: 19970506  
Last Updated on STN: 19970506

Entered Medline: 19970424

L12 ANSWER 3 OF 4 MEDLINE on STN  
ACCESSION NUMBER: 89097255 MEDLINE  
DOCUMENT NUMBER: PubMed ID: 2911352  
TITLE: The mucosal vascular addressin is a  
tissue-specific endothelial cell adhesion molecule for  
circulating lymphocytes.  
AUTHOR: Nakache M; Berg E L; Streeter P R; Butcher E C  
CORPORATE SOURCE: Department of Pathology, Stanford University, California  
94305.  
SOURCE: Nature, (1989 Jan 12) 337 (6203) 179-81.  
Journal code: 0410462. ISSN: 0028-0836.  
PUB. COUNTRY: ENGLAND: United Kingdom  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 198902  
ENTRY DATE: Entered STN: 19900308  
Last Updated on STN: 19900308  
Entered Medline: 19890216

L12 ANSWER 4 OF 4 MEDLINE on STN  
ACCESSION NUMBER: 88331082 MEDLINE  
DOCUMENT NUMBER: PubMed ID: 3138247  
TITLE: Tumor necrosis factor and immune interferon act  
in concert to slow the lateral diffusion of proteins and  
lipids in human endothelial cell membranes.  
AUTHOR: Stolpen A H; Golan D E; Pober J S  
CORPORATE SOURCE: Department of Biological Chemistry and Molecular  
Pharmacology, Harvard Medical School, Boston, Massachusetts  
02115.  
CONTRACT NUMBER: GM 07753 (NIGMS)  
HL 32854 (NHLBI)  
HL 36003 (NHLBI)  
SOURCE: Journal of cell biology, (1988 Aug) 107 (2) 781-9.  
Journal code: 0375356. ISSN: 0021-9525.  
PUB. COUNTRY: United States  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 198810  
ENTRY DATE: Entered STN: 19900308  
Last Updated on STN: 19970203  
Entered Medline: 19881021

=> d kwic 2

L12 ANSWER 2 OF 4 MEDLINE on STN  
AB BACKGROUND: Anti-phospholipid antibodies (aPLs) were  
associated with an ongoing prothrombotic state in patients with systemic  
lupus erythematosus (SLE). Because aPLs are able to. . . patients.  
METHODS AND RESULTS: We measured aPLs, anti-EC antibodies, circulating  
levels of prothrombin fragment F1 + 2 (F1 + 2), tumor necrosis  
factor-alpha (TNF-alpha), tissue-type plasminogen activator (TPA), and von  
Willebrand factor (vWF) in 43 SLE patients and 25 healthy subjects.. . .  
P = .0006) only in aPL(+) patients. Endothelial perturbation was closely  
associated with high values of TNF-alpha (P = .0001), anti-  
phospholipid (P = .001), and anti-EC antibodies (P =  
.012). In 31 patients without a clinical history of thrombosis followed  
up for 3 years, aPL(+) patients with. . .  
CT Check Tags: Female; Male  
Adult

\*Antibodies, Antiphospholipid: AN, analysis  
 \*Endothelium, Vascular: PP, physiopathology  
 Humans  
 Lupus Erythematosus, Systemic: CO, complications  
 \*Lupus Erythematosus, Systemic: IM, immunology  
 \*Lupus Erythematosus, Systemic: PP, physiopathology  
 Middle. . .

=> d kwic 3

L12 ANSWER 3 OF 4 MEDLINE on STN

TI The mucosal vascular addressin is a tissue-specific endothelial cell adhesion molecule for circulating lymphocytes.

AB . . . to play a part in cellular positioning in a variety of systems, for example during neural development, the metastasis of neoplasms, and the tissue-specific homing of lymphocytes. The extravasation of blood-borne lymphocytes is regulated by interactions with the endothelium of specialised. . . peripheral lymph nodes, another in mucosal lymphoid organs, and a third in inflamed synovium. We have previously identified a tissue-specific 'vascular addressin' in the mouse which is selectively expressed by venules mediating lymphocyte-homing into mucosal tissues. To determine whether this addressin is a specific adhesion molecule for lymphocytes, we have isolated it by monoclonal antibody-affinity chromatography and inserted it into supported phospholipid planar membranes. Lymphocytes bind to membranes containing the addressin, but not to phospholipid bilayers or to control glycophorin-reconstituted membranes. Only. . . HEV-specific or HEV-non-binding cell lines do not bind. Binding is blocked by anti-addressin antibody MECA-367. We conclude that the mucosal vascular addressin is a tissue-specific endothelial cell-adhesion molecule for lymphocytes, and suggest that it could regulate lymphocyte traffic into mucosal tissues. . .

CT Animals

Antibodies

\*Antigens, Surface: IP, isolation & purification

Antigens, Surface: PH, physiology

Cell Adhesion

Cell Adhesion Molecules

Cell Line

\*Endothelium, Vascular: PH, physiology

\*Lymphocytes: PH, physiology

Lymphoma: PP, physiopathology

\*Membrane Glycoproteins: IP, isolation & purification

Mice

Mice, Inbred BALB C

=> file cancerlit

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

4.20

4.41

FILE 'CANCERLIT' ENTERED AT 12:59:15 ON 16 MAR 2005

FILE COVERS 1963 TO 15 Nov 2002 (20021115/ED)

On July 28, 2002, CANCERLIT was reloaded. See HELP RLOAD for details.

CANCERLIT thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2002 vocabulary. Enter HELP THESAURUS for details.

This file contains CAS Registry Numbers for easy and accurate substance

identification.

=> s phospholipid? or phosphatidyl?

6770 PHOSPHOLIPID?

11354 PHOSPHATIDYL?

L13 15945 PHOSPHOLIPID? OR PHOSPHATIDYL?

=> s antibod?

L14 162627 ANTIBOD?

=> s l13 (s) l14

L15 1284 L13 (S) L14

=> s cancer? or tumor? or neoplas?

413999 CANCER?

629285 TUMOR?

902289 NEOPLAS?

L16 1221530 CANCER? OR TUMOR? OR NEOPLAS?

=> s l15 and l16

L17 653 L15 AND L16

=> s l17 not py>1998

354668 PY>1998

L18 496 L17 NOT PY>1998

=> s l18 and vascula?

54276 VASCULA?

L19 12 L18 AND VASCULA?

=> s l19 not l12

5626 PHOSPHOLIPID?/AB

8229 PHOSPHATIDYL?/AB

162627 ANTIBOD?

1273 L8 (S) L2

413999 CANCER?

629285 TUMOR?

902289 NEOPLAS?

354668 PY>1998

54276 VASCULA?

L20 0 L19 NOT L12

=> d l19 ibib 1-6

L19 ANSWER 1 OF 12 CANCERLIT on STN

ACCESSION NUMBER: 1999002666 CANCERLIT

DOCUMENT NUMBER: 99002666 PubMed ID: 9788617

TITLE: Infarction of solid Hodgkin's tumors in mice by antibody-directed targeting of tissue factor to tumor vasculature.

AUTHOR: Ran S; Gao B; Duffy S; Watkins L; Rote N; Thorpe P E

CORPORATE SOURCE: Hamon Center for Therapeutic Oncology Research and the Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas 75235, USA.

CONTRACT NUMBER: 1R01CA74951-01 (NCI)

5R01CA54168-05 (NCI)

SOURCE: CANCER RESEARCH, (1998 Oct 15) 58 (20) 4646-53.  
Journal code: 2984705R. ISSN: 0008-5472.

PUB. COUNTRY: United States

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: MEDLINE; Priority Journals

OTHER SOURCE: MEDLINE 1999002666

ENTRY MONTH: 199811

ENTRY DATE: Entered STN: 19990122  
Last Updated on STN: 19990122

L19 ANSWER 2 OF 12 CANCERLIT on STN  
ACCESSION NUMBER: 1998416166 CANCERLIT  
DOCUMENT NUMBER: 98416166 PubMed ID: 9743521  
TITLE: Urokinase receptor (CD87) regulates leukocyte recruitment  
via beta 2 integrins in vivo.  
AUTHOR: May A E; Kanse S M; Lund L R; Gisler R H; Imhof B A;  
Preissner K T  
CORPORATE SOURCE: Haemostasis Research Unit, Max-Planck Institute,  
Kerckhoff-Klinik, D-61231 Bad Nauheim, Germany.  
SOURCE: JOURNAL OF EXPERIMENTAL MEDICINE, (1998 Sep 21) 188 (6)  
1029-37.  
Journal code: 2985109R. ISSN: 0022-1007.  
PUB. COUNTRY: United States  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: MEDLINE; Priority Journals  
OTHER SOURCE: MEDLINE 1998416166  
ENTRY MONTH: 199810  
ENTRY DATE: Entered STN: 19981118  
Last Updated on STN: 19981118

L19 ANSWER 3 OF 12 CANCERLIT on STN  
ACCESSION NUMBER: 97612102 CANCERLIT  
DOCUMENT NUMBER: 97612102  
TITLE: Increase in vasculature in human breast  
cancer xenografts in nude mice treated with  
hexadecylphosphocholine (Meeting abstract).  
AUTHOR: Safa O; Parkin S M; Bibby M C  
CORPORATE SOURCE: Department of Biomedical Sciences, University of Bradford,  
Bradford, West Yorkshire, BD7 1DP, UK.  
SOURCE: Br J Cancer, (1996) 73 (Suppl 26) 24.  
ISSN: 0007-0920.  
DOCUMENT TYPE: (MEETING ABSTRACTS)  
LANGUAGE: English  
FILE SEGMENT: Institute for Cell and Developmental Biology  
ENTRY MONTH: 199706  
ENTRY DATE: Entered STN: 19980417  
Last Updated on STN: 19980417

L19 ANSWER 4 OF 12 CANCERLIT on STN  
ACCESSION NUMBER: 97275152 CANCERLIT  
DOCUMENT NUMBER: 97275152 PubMed ID: 9129046  
TITLE: CD24, a mucin-type glycoprotein, is a ligand for P-selectin  
on human tumor cells.  
AUTHOR: Aigner S; Sthoeger Z M; Fogel M; Weber E; Zarn J; Ruppert  
M; Zeller Y; Vestweber D; Stahel R; Sammar M; Altevogt P  
CORPORATE SOURCE: Tumor Immunology Programme, German Cancer Research Center,  
Heidelberg.  
SOURCE: BLOOD, (1997 May 1) 89 (9) 3385-95.  
Journal code: 7603509. ISSN: 0006-4971.  
PUB. COUNTRY: United States  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: MEDLINE; Abridged Index Medicus Journals; Priority Journals  
OTHER SOURCE: MEDLINE 97275152  
ENTRY MONTH: 199706  
ENTRY DATE: Entered STN: 19970711  
Last Updated on STN: 19970711

L19 ANSWER 5 OF 12 CANCERLIT on STN  
ACCESSION NUMBER: 97064647 CANCERLIT



DOCUMENT NUMBER: 97064647 PubMed ID: 8908197  
TITLE: Tumor cell-conditioned medium stimulates  
expression of the urokinase receptor in vascular  
endothelial cells.  
AUTHOR: Seghezzi G; Marelli R; Mandriota S J; Nolli M L; Mazziere  
R; Mignatti P  
CORPORATE SOURCE: Dipartimento di Genetica e Microbiologia, Universita di  
Pavia, Italy.  
SOURCE: JOURNAL OF CELLULAR PHYSIOLOGY, (1996 Nov) 169 (2) 300-8.  
Journal code: 0050222. ISSN: 0021-9541.  
PUB. COUNTRY: United States  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: MEDLINE; Priority Journals  
OTHER SOURCE: MEDLINE 97064647  
ENTRY MONTH: 199612  
ENTRY DATE: Entered STN: 19970108  
Last Updated on STN: 19970509

L19 ANSWER 6 OF 12 CANCERLIT on STN  
ACCESSION NUMBER: 96625383 CANCERLIT  
DOCUMENT NUMBER: 96625383  
TITLE: In vivo targeting of liposomal drug carriers.  
AUTHOR: Longman S A  
CORPORATE SOURCE: Univ. of British Columbia, Canada.  
SOURCE: Diss Abstr Int [B], (1995) 56 (4) 1998.  
ISSN: 0419-4217.  
DOCUMENT TYPE: (THESIS)  
LANGUAGE: English  
FILE SEGMENT: Institute for Cell and Developmental Biology  
ENTRY MONTH: 199606  
ENTRY DATE: Entered STN: 19970509  
Last Updated on STN: 19970509

=> FIL STNGUIDE  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
3.10	7.51

FULL ESTIMATED COST

FILE 'STNGUIDE' ENTERED AT 13:02:22 ON 16 MAR 2005  
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE  
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.  
LAST RELOADED: Mar 11, 2005 (20050311/UP).

=> d 119 ibib 7-12  
YOU HAVE REQUESTED DATA FROM FILE 'CANCERLIT' - CONTINUE? (Y)/N:y

L19 ANSWER 7 OF 12 CANCERLIT on STN  
ACCESSION NUMBER: 94065586 CANCERLIT  
DOCUMENT NUMBER: 94065586 PubMed ID: 7504060  
TITLE: A critical role for monocytes and CD14 in endotoxin-induced  
endothelial cell activation.  
AUTHOR: Pugin J; Ulevitch R J; Tobias P S  
CORPORATE SOURCE: Department of Immunology, Scripps Research Institute, La  
Jolla, California 92037.  
CONTRACT NUMBER: AI-32021 (NIAID)  
GM-37696 (NIGMS)  
SOURCE: JOURNAL OF EXPERIMENTAL MEDICINE, (1993 Dec 1) 178 (6)

2193-200.  
Journal code: 2985109R. ISSN: 0022-1007.  
PUB. COUNTRY: United States  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: MEDLINE; Priority Journals  
OTHER SOURCE: MEDLINE 94065586  
ENTRY MONTH: 199312  
ENTRY DATE: Entered STN: 19941107  
Last Updated on STN: 19960517

L19 ANSWER 8 OF 12 CANCERLIT on STN  
ACCESSION NUMBER: 93112942 CANCERLIT  
DOCUMENT NUMBER: 93112942 PubMed ID: 7678062  
TITLE: Expression of integrins and examination of their adhesive  
function in normal and leukemic hematopoietic cells.  
AUTHOR: Liesveld J L; Winslow J M; Frediani K E; Ryan D H; Abboud C  
N  
CORPORATE SOURCE: Hematology Unit, University of Rochester Medical Center, NY  
14642.  
CONTRACT NUMBER: CA-32737 (NCI)  
HL-18208 (NHLBI)  
K11 HL02385-01A1 (NHLBI)  
+  
SOURCE: BLOOD, (1993 Jan 1) 81 (1) 112-21.  
Journal code: 7603509. ISSN: 0006-4971.  
PUB. COUNTRY: United States  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: MEDLINE; Abridged Index Medicus Journals; Priority Journals  
OTHER SOURCE: MEDLINE 93112942  
ENTRY MONTH: 199302  
ENTRY DATE: Entered STN: 19941107  
Last Updated on STN: 19970509

L19 ANSWER 9 OF 12 CANCERLIT on STN  
ACCESSION NUMBER: 89097255 CANCERLIT  
DOCUMENT NUMBER: 89097255 PubMed ID: 2911352  
TITLE: The mucosal vascular addressin is a  
tissue-specific endothelial cell adhesion molecule for  
circulating lymphocytes.  
AUTHOR: Nakache M; Berg E L; Streeter P R; Butcher E C  
CORPORATE SOURCE: Department of Pathology, Stanford University, California  
94305.  
SOURCE: NATURE, (1989 Jan 12) 337 (6203) 179-81.  
Journal code: 0410462. ISSN: 0028-0836.  
PUB. COUNTRY: ENGLAND: United Kingdom  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: MEDLINE; Priority Journals  
OTHER SOURCE: MEDLINE 89097255  
ENTRY MONTH: 198902  
ENTRY DATE: Entered STN: 19941107  
Last Updated on STN: 19941107

L19 ANSWER 10 OF 12 CANCERLIT on STN  
ACCESSION NUMBER: 88331082 CANCERLIT  
DOCUMENT NUMBER: 88331082 PubMed ID: 3138247  
TITLE: Tumor necrosis factor and immune interferon act  
in concert to slow the lateral diffusion of proteins and  
lipids in human endothelial cell membranes.  
AUTHOR: Stolpen A H; Golan D E; Poher J S  
CORPORATE SOURCE: Department of Biological Chemistry and Molecular  
Pharmacology, Harvard Medical School, Boston, Massachusetts

02115.  
CONTRACT NUMBER: GM 07753 (NIGMS)  
HL 32854 (NHLBI)  
HL 36003 (NHLBI)  
SOURCE: JOURNAL OF CELL BIOLOGY, (1988 Aug) 107 (2) 781-9.  
Journal code: 0375356. ISSN: 0021-9525.  
PUB. COUNTRY: United States  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: MEDLINE; Priority Journals  
OTHER SOURCE: MEDLINE 88331082  
ENTRY MONTH: 198810  
ENTRY DATE: Entered STN: 19941107  
Last Updated on STN: 19941107

L19 ANSWER 11 OF 12 CANCERLIT on STN  
ACCESSION NUMBER: 87192482 CANCERLIT  
DOCUMENT NUMBER: 87192482 PubMed ID: 2437001  
TITLE: Human hepatocellular carcinoma: cross-reactive and  
idiotypic antigens associated with malignant transformation  
of epithelial cells.  
AUTHOR: Wiedmann K H; Trejdosiwicz L K; Southgate J; Thomas H C  
SOURCE: HEPATOLOGY, (1987 May-Jun) 7 (3) 543-50.  
Journal code: 8302946. ISSN: 0270-9139.  
PUB. COUNTRY: United States  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: MEDLINE; Priority Journals  
OTHER SOURCE: MEDLINE 87192482  
ENTRY MONTH: 198706  
ENTRY DATE: Entered STN: 19941107  
Last Updated on STN: 19960517

L19 ANSWER 12 OF 12 CANCERLIT on STN  
ACCESSION NUMBER: 76614630 CANCERLIT  
DOCUMENT NUMBER: 76614630  
TITLE: COMPLICATIONS OF LYMPHOGRAPHY. REPORT OF FIVE CASES.  
AUTHOR: Poirier R; Locher C; Kleisbauer J P; Laval P  
CORPORATE SOURCE: Hopital Michel Levy, 84, rue de Lodi, 13006 Marseille,  
France.  
SOURCE: Sem Hop Paris, (1975) 51 (49) 3001-3008.  
ISSN: 0037-1777.  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: French  
FILE SEGMENT: Institute for Cell and Developmental Biology  
ENTRY MONTH: 197609  
ENTRY DATE: Entered STN: 19941107  
Last Updated on STN: 19941107

=> file dissab		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.06	9.21

FILE 'DISSABS' ENTERED AT 13:03:42 ON 16 MAR 2005  
COPYRIGHT (C) 2005 ProQuest Information and Learning Company; All Rights Reserved.

FILE COVERS 1861 TO 25 FEB 2005 (20050225/ED)

Only fair use as provided by the United States copyright law is permitted. PROQUEST INFORMATION AND LEARNING COMPANY MAKES NO WARRANTY REGARDING THE ACCURACY, COMPLETENESS OR TIMELINESS OF THE LICENSED MATERIALS OR ANY WARRANTY, EXPRESS OR IMPLIED,

INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, AND SHALL NOT BE LIABLE FOR DAMAGES OF ANY KIND OR LOST PROFITS OR OTHER CLAIMS RELATED TO THE LICENSED MATERIALS OR THEIR USE.

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.41	9.62

FILE 'CAPLUS' ENTERED AT 13:04:03 ON 16 MAR 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 16 Mar 2005 VOL 142 ISS 12

FILE LAST UPDATED: 15 Mar 2005 (20050315/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s phosphatidyl?

L21 90930 PHOSPHATIDYL?

=> s l21/ab

L22 67894 (PHOSPHATIDYL?/AB)

=> s antibod?

L23 427880 ANTIBOD?

=> s l22 and l23

L24 3952 L22 AND L23

=> s l23/ab

L25 368747 (ANTIBOD?/AB)

=> s l25 and l22

L26 3660 L25 AND L22

=> s cancer? or neoplas? or tumor?

252503 CANCER?

401128 NEOPLAS?

383797 TUMOR?

L27 635338 CANCER? OR NEOPLAS? OR TUMOR?

=> s l27 and l26

L28 464 L27 AND L26

=> s l28 not py>1998

6069320 PY>1998

L29 206 L28 NOT PY>1998

=> s 129 and vascula?  
146676 VASCULA?  
L30 7 L29 AND VASCULA?

=> d ibib 1-4

L30 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 1998:671828 CAPLUS  
DOCUMENT NUMBER: 130:47214  
TITLE: Infarction of solid Hodgkin's tumors in mice  
by antibody-directed targeting of tissue factor to  
tumor vasculature  
AUTHOR(S): Ran, Sophia; Gao, Boning; Duffy, Steve; Watkins,  
Linda; Rote, Neal; Thorpe, Philip E.  
CORPORATE SOURCE: Hamon Center for Therapeutic Oncology Research and the  
Department of Pharmacology, University of Texas  
Southwestern Medical Center, Dallas, TX, 75235, USA  
SOURCE: Cancer Research (1998), 58(20), 4646-4653  
CODEN: CNREA8; ISSN: 0008-5472  
PUBLISHER: American Association for Cancer Research  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L30 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 1998:50483 CAPLUS  
DOCUMENT NUMBER: 128:119465  
TITLE: Long-circulating immunoliposome targeting in animal  
models  
AUTHOR(S): Maruyama, Kazuo  
CORPORATE SOURCE: Faculty of Pharmaceutical Sciences, Teikyo University,  
Kanagawa, 199-01, Japan  
SOURCE: Journal of Liposome Research (1997), 7(4), 363-389  
CODEN: JLREE7; ISSN: 0898-2104  
PUBLISHER: Marcel Dekker, Inc.  
DOCUMENT TYPE: Journal; General Review  
LANGUAGE: English  
REFERENCE COUNT: 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L30 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 1997:288689 CAPLUS  
DOCUMENT NUMBER: 126:341801  
TITLE: CD24, a mucin-type glycoprotein, is a ligand for  
P-selectin on human tumor cells  
AUTHOR(S): Aigner, Silke; Sthoeger, Zev M.; Fogel, Mina; Weber,  
Erich; Zarn, Jurg; Ruppert, Michael; Zeller, Yvonka;  
Vestweber, Dietmar; Stahel, Rolf; Sammar, Marei;  
Altevogt, Peter  
CORPORATE SOURCE: Tumor Immunol. Programme, German Cancer Res. Cent.,  
Heidelberg, D-69120, Germany  
SOURCE: Blood (1997), 89(9), 3385-3395  
CODEN: BLOOAW; ISSN: 0006-4971  
PUBLISHER: Saunders  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
REFERENCE COUNT: 58 THERE ARE 58 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L30 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 1997:224387 CAPLUS  
DOCUMENT NUMBER: 126:268444  
TITLE: Targetability of PEG-immunoliposomes conjugating

antibodies at the ends of PEG chains  
AUTHOR(S): Maruyama, K.; Takizawa, T.; Iwatsuru, M.; Tagawa, T.;  
Nagaike, K.  
CORPORATE SOURCE: Faculty of Pharmaceutical Sci., Teikyo Univ.,  
Kanagawa, 199-01, Japan  
SOURCE: Polymer Preprints (American Chemical Society, Division  
of Polymer Chemistry) (1997), 38(1), 541-542  
CODEN: ACPPAY; ISSN: 0032-3934  
PUBLISHER: American Chemical Society, Division of Polymer  
Chemistry  
DOCUMENT TYPE: Journal  
LANGUAGE: English

=> d kwic 4

L30 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN  
AB Phosphatidylethanolamine derivs. of PEG with terminal CO<sub>2</sub>H or  
maleimidyl groups were incorporated into phosphatidylcholine  
-cholesterol liposomes, and the terminal functional groups were conjugated  
with monoclonal antibodies. An antibody to pulmonary  
endothelial cells, bound to PEG chains on liposomes, bound to the lung  
endothelial surface after i.v. injection to a greater extent than  
antibody bound directly to the liposome surface, and to a much  
greater extent than antibody bound to the surface of liposomes  
which also bore PEG chains. Similar liposomes bearing an antibody  
to carcinoembryonic antigen (CEA) at the end of PEG chains, when injected  
into mice bearing CEA-pos. human gastric cancer cells, showed  
relatively high accumulation into the tumor cells. Accumulation  
of liposomes bearing anti-CEA Fab' fragment-terminated PEG chains was  
still better, owing to decreased reticuloendothelial clearance of Fab'  
compared to intact antibody.  
ST liposome PEG antibody tumor targeting  
IT Lung  
(drug targeting to vascular endothelium of; targetability of  
PEG-immunoliposomes bearing antibodies at ends of PEG chains)

=> d ibib 5-7

L30 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 1997:192489 CAPLUS  
DOCUMENT NUMBER: 126:268390  
TITLE: Targeting efficiency of PEG-immunoliposome-conjugated  
antibodies at PEG  
AUTHOR(S): Maruyama, Kazuo; Takizawa, Tomoko; Takahashi, Nobuya;  
Tagawa, Toshiaki; Nagaike, Kazuhiro; Iwatsuru,  
Motoharu  
CORPORATE SOURCE: Fac. Pharmaceutical Sci., Teikyo Univ., Sagamiko,  
199-01, Japan  
SOURCE: Advanced Drug Delivery Reviews (1997), 24(2,3),  
235-242  
CODEN: ADDREP; ISSN: 0169-409X  
PUBLISHER: Elsevier  
DOCUMENT TYPE: Journal  
LANGUAGE: English

L30 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 1996:661955 CAPLUS  
DOCUMENT NUMBER: 125:298105  
TITLE: Tumor cell-conditioned medium stimulates  
expression of the urokinase receptor in  
vascular endothelial cells  
AUTHOR(S): Seghezzi, Graziano; Marelli, Rosaria; Mandriota,

Stefano J.; Nolli, Maria Luisa; Mazzieri, Roberta;  
Mignatti, Paolo  
CORPORATE SOURCE: Dip. Genet. Microbiol., Univ. Pavia, Pavia, 27100,  
Italy  
SOURCE: Journal of Cellular Physiology (1996), 169(2), 300-308  
CODEN: JCLLAX; ISSN: 0021-9541  
PUBLISHER: Wiley-Liss  
DOCUMENT TYPE: Journal  
LANGUAGE: English

L30 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 1995:318350 CAPLUS  
DOCUMENT NUMBER: 122:103660  
TITLE: Expression of glycoposphatidylinositol-anchored and  
-non-anchored isoforms of vascular cell  
adhesion molecule 1 in murine stromal and endothelial  
cells  
AUTHOR(S): Kinashi, Tatsuo; St. Pierre, Yves; Springer, Timothy  
A.  
CORPORATE SOURCE: Cent. Blood Res., Harvard Med. Sch., Boston, MA, USA  
SOURCE: Journal of Leukocyte Biology (1995), 57(1), 168-73  
CODEN: JLBIE7; ISSN: 0741-5400  
PUBLISHER: Federation of American Societies for Experimental  
Biology  
DOCUMENT TYPE: Journal  
LANGUAGE: English

=> d kwic 7

L30 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN  
TI Expression of glycoposphatidylinositol-anchored and -non-anchored  
isoforms of vascular cell adhesion molecule 1 in murine stromal  
and endothelial cells  
AB Monoclonal antibodies to murine vascular cell adhesion  
mol.-1 (VCAM-1, CD106) revealed not only the expected VCAM-1 mol. with an  
apparent mol. weight of 100 kDa, . . . kDa proteins were closely related.  
The 46 kDa, but not 100 kDa protein, was cleaved from the cell surface  
with phosphatidylinositol-specific phospholipase C (PI-PLC),  
showing that the 46 kDa protein was a GPI-linked mol. The 46 kDa and 100  
kDa isoforms. . .  
ST VCAM1 isoform stroma endothelium; tumor necrosis factor VCAM1  
glycoposphatidylinositol anchor  
IT Sialoglycoproteins  
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); MFM  
(Metabolic formation); BIOL (Biological study); FORM (Formation,  
nonpreparative); OCCU (Occurrence)  
(VCAM-1 (vascular cell adhesion mol. 1),  
glycoposphatidylinositol-anchored and -non-anchored isoforms of VCAM-1  
in stromal and endothelial cells)  
IT Lymphokines and Cytokines  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
study, unclassified); BIOL (Biological study)  
(tumor necrosis factor- $\alpha$ , tumor necrosis  
factor- $\alpha$  stimulates VCAM-1 isoform expression in endothelial  
cells)

=> d kwic 6

L30 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN  
TI Tumor cell-conditioned medium stimulates expression of the  
urokinase receptor in vascular endothelial cells  
AB . . . hepatoma cells or mouse S180 sarcoma cells induces in vitro

angiogenesis and stimulates production of urokinase plasminogen activator (uPA) in vascular endothelial cells. These activities are mediated by a 3.5-10 kDa, heparin-binding peptide that upregulates endothelial cell expression of basic fibroblast. . . medium rapidly induces a 4- to 5-fold increase in cell-bound uPA activity and in the high-affinity binding of 125I-prouPA to vascular endothelial cells. Ligand blotting and purification expts. show an equivalent increase in

the

synthesis of a cell surface protein corresponding to the endothelial cell uPA receptor (uPAR) on the basis of Mr (45-50 kDa) and sensitivity to phosphatidylinositol-specific phospholipase C (PI-PLC). The tumor cell-conditioned media also upregulate uPAR mRNA levels in endothelial cells. Thus, the increase in uPA binding capacity of endothelial cells. . . mediated by an increased expression of uPAR. The uPAR-inducing activity of SK-Hep1 or S180 cell-conditioned medium is not neutralized by antibodies to bFGF, and is associated with a peptide that has a Mr higher than 10 kDa and no affinity for. . .

ST urokinase plasminogen activator receptor neoplasm cell

IT Animal cell line

(S180; tumor cell-conditioned medium stimulates expression of the urokinase receptor in vascular endothelial cells)

IT Neoplasm

(tumor cell-conditioned medium stimulates expression of the urokinase receptor in vascular endothelial cells)

IT Animal cell line

(SK-hep-1, tumor cell-conditioned medium stimulates expression of the urokinase receptor in vascular endothelial cells)

IT Blood vessel

(endothelium, tumor cell-conditioned medium stimulates expression of the urokinase receptor in vascular endothelial cells)

IT Receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (urokinase-type plasminogen activator, tumor cell-conditioned medium stimulates expression of the urokinase receptor in vascular endothelial cells)

IT 9039-53-6, Urokinase plasminogen activator

RL: BSU (Biological study, unclassified); BIOL (Biological study) (tumor cell-conditioned medium stimulates expression of the urokinase receptor in vascular endothelial cells)

=> file pctfull

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

33.02

42.64

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-2.19

-2.19

FILE 'PCTFULL' ENTERED AT 13:07:31 ON 16 MAR 2005

COPYRIGHT (C) 2005 Univentio

FILE LAST UPDATED:

15 MAR 2005

<20050315/UP>

MOST RECENT UPDATE WEEK:

200510

<200510/EW>

FILE COVERS 1978 TO DATE

>>> IMAGES ARE AVAILABLE ONLINE AND FOR EMAIL-PRINTS <<<

=> s phosphatidyl?

L31 13823 PHOSPHATIDYL?



=> s 131/ab  
L32 322 (PHOSPHATIDYL?/AB)

=> s antibod?  
L33 76152 ANTIBOD?

=> s 133/ab  
L34 14004 (ANTIBOD?/AB)

=> s 134 and 132  
L35 28 L34 AND L32

=> s cancer? or neopals? or tumor?  
66594 CANCER?  
2 NEOPALS?  
56059 TUMOR?  
L36 82019 CANCER? OR NEOPALS? OR TUMOR?

=> s 136 and 135  
L37 19 L36 AND L35

=> s 137 not py>1998  
595322 PY>1998  
L38 8 L37 NOT PY>1998

=> d ibib 1-4

L38 ANSWER 1 OF 8 PCTFULL COPYRIGHT 2005 Univentio on STN  
ACCESSION NUMBER: 1998056911 PCTFULL ED 20020514  
TITLE (ENGLISH): HUMAN PHOSPHATIDYLINOSITOL TRANSFER PROTEIN GAMMA  
TITLE (FRENCH): PROTEINE GAMMA HUMAINE DE TRANSFERT DE PHOSPHATIDYL  
INOSITOL  
INVENTOR(S): HILLMAN, Jennifer, L.;  
GOLI, Surya, K.  
PATENT ASSIGNEE(S): INCYTE PHARMACEUTICALS, INC.;  
HILLMAN, Jennifer, L.;  
GOLI, Surya, K.  
LANGUAGE OF PUBL.: English  
DOCUMENT TYPE: Patent  
PATENT INFORMATION:  

NUMBER	KIND	DATE
-----		
WO 9856911	A1	19981217

  
DESIGNATED STATES  
W: AT AU BR CA CH CN DE DK ES FI GB IL JP KR MX NO NZ RU  
SE SG US GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD  
RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC  
NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG  
APPLICATION INFO.: WO 1998-US11917 A 19980610  
PRIORITY INFO.: 1997-8/872,961 19970611  
US 1997-8/872,961 19970611

L38 ANSWER 2 OF 8 PCTFULL COPYRIGHT 2005 Univentio on STN  
ACCESSION NUMBER: 1998020118 PCTFULL ED 20020514  
TITLE (ENGLISH): MODIFIED PROTEIN C AND METHODS OF USE THEREOF  
TITLE (FRENCH): PROTEINE C MODIFIEE ET PROCEDES D'UTILISATION  
CORRESPONDANTS  
INVENTOR(S): ESMON, Charles, T.;  
SMIRNOV, Mikhail  
PATENT ASSIGNEE(S): OKLAHOMA MEDICAL RESEARCH FOUNDATION  
LANGUAGE OF PUBL.: English  
DOCUMENT TYPE: Patent  
PATENT INFORMATION:  

NUMBER	KIND	DATE
--------	------	------

	-----	
	WO 9820118	A1 19980514
DESIGNATED STATES		
W:	AU CA JP AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL	
	PT SE	
APPLICATION INFO.:	WO 1997-US20376	A 19971107
PRIORITY INFO.:	1996-8/745,254	19961108
	US 1996-8/745,254	19961108
	US 1997-60/053,768	19970725
	US 1997-60/053,768	19970725
L38 ANSWER 3 OF 8	PCTFULL	COPYRIGHT 2005 Univentio on STN
ACCESSION NUMBER:	1998015629	PCTFULL ED 20020514
TITLE (ENGLISH):	BINDING PROTEINS FOR PHOSPHOINOSITIDES, GRP1 OR GENERAL	
	RECEPTOR 1 FOR PHOSPHOINOSITIDE	
TITLE (FRENCH):	PROTEINES DE LIAISON POUR PHOSPHOINOSITIDES, GRP1 OU	
	RECEPTEUR GENERAL 1 POUR PHOSPHOINOSITIDE	
INVENTOR(S):	CZECH, Michael, P.;	
	KLARLUND, Jes, K.	
PATENT ASSIGNEE(S):	UNIVERSITY OF MASSACHUSETTS;	
	CZECH, Michael, P.;	
	KLARLUND, Jes, K.	
LANGUAGE OF PUBL.:	English	
DOCUMENT TYPE:	Patent	
PATENT INFORMATION:		
	NUMBER	KIND DATE
	-----	-----
	WO 9815629	A1 19980416
DESIGNATED STATES		
W:	AU CA JP KR US AT BE CH DE DK ES FI FR GB GR IE IT LU	
	MC NL PT SE	
APPLICATION INFO.:	WO 1997-US18152	A 19971007
PRIORITY INFO.:	1996-8/729,834	19961007
	US 1996-8/729,834	19961007
L38 ANSWER 4 OF 8	PCTFULL	COPYRIGHT 2005 Univentio on STN
ACCESSION NUMBER:	1997049818	PCTFULL ED 20020514
TITLE (ENGLISH):	G-BETA-GAMMA REGULATED PHOSPHATIDYLINOSITOL-3' KINASE	
TITLE (FRENCH):	PHOSPHATIDYLINOTISOL-3 KINASE REGULEE PAR UNE PROTEINE	
	G BETA-GAMMA	
INVENTOR(S):	STEPHENS, Len;	
	HAWKINS, Phillip, T.;	
	BRASELMANN, Sylvia	
PATENT ASSIGNEE(S):	ONYX PHARMACEUTICALS	
LANGUAGE OF PUBL.:	English	
DOCUMENT TYPE:	Patent	
PATENT INFORMATION:		
	NUMBER	KIND DATE
	-----	-----
	WO 9749818	A2 19971231
DESIGNATED STATES		
W:	AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE GH HU IL	
	IS JP KG KP KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ	
	PL RO RU SG SI SK SL TJ TM TR TT UA UZ VN YU GH KE LS	
	MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE	
	DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI	
	CM GA GN ML MR NE SN TD TG	
APPLICATION INFO.:	WO 1997-US11219	A 19970626
PRIORITY INFO.:	1996-8/672,211	19960627
	US 1996-8/672,211	19960627

L38 ANSWER 5 OF 8 PCTFULL COPYRIGHT 2005 Univentio on STN  
 ACCESSION NUMBER: 1997019101 PCTFULL ED 20020514  
 TITLE (ENGLISH): NOVEL GRB2 ASSOCIATING POLYPEPTIDES AND NUCLEIC ACIDS  
 ENCODING THEREFOR  
 TITLE (FRENCH): NOUVEAUX POLYPEPTIDES S'ASSOCIANT A LA PROTEINE GRB2 ET  
 ACIDES NUCLEIQUES LES CODANT  
 INVENTOR(S): POT, David, A.;  
 WILLIAMS, Lewis, T.;  
 JEFFERSON, Anne, Bennett;  
 MAJERUS, Philip, W.  
 PATENT ASSIGNEE(S): THE REGENTS OF THE UNIVERSITY OF CALIFORNIA;  
 WASHINGTON UNIVERSITY  
 LANGUAGE OF PUBL.: English  
 DOCUMENT TYPE: Patent  
 PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9719101	A1	19970529

DESIGNATED STATES

W:

AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE  
 ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT  
 LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI  
 SK TJ TM TR TT UA UG UZ VN KE LS MW SD SZ UG AM AZ BY  
 KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT  
 LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD  
 TG

APPLICATION INFO.: WO 1996-US16671 A 19961018  
 PRIORITY INFO.: 1995-8/560,005 19951117  
 US 1995-8/560,005 19951117

L38 ANSWER 6 OF 8 PCTFULL COPYRIGHT 2005 Univentio on STN  
 ACCESSION NUMBER: 1996012024 PCTFULL ED 20020514  
 TITLE (ENGLISH): CLONING, EXPRESSION AND CHARACTERISATION OF A NOVEL  
 FORM OF PHOSPHATIDYLINOSITOL-3-KINASE  
 TITLE (FRENCH): CLONAGE, EXPRESSION ET CARACTERISATION D'UNE NOUVELLE  
 FORME DE PHOSPHATIDYLINOSITOL-3-KINASE  
 INVENTOR(S): STOYANOV, Borislav;  
 HANCK, Theodor;  
 WETZKER, Reinhard  
 PATENT ASSIGNEE(S): MAX-PLANCK-GESELLSCHAFT ZUR FoerDERUNG DER  
 WISSENSCHAFTEN E.V., BERLIN;  
 STOYANOV, Borislav;  
 HANCK, Theodor;  
 WETZKER, Reinhard  
 LANGUAGE OF PUBL.: German  
 DOCUMENT TYPE: Patent  
 PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9612024	A1	19960425

DESIGNATED STATES

W:

CA JP US AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT  
 SE

APPLICATION INFO.: WO 1995-EP3990 A 19951010  
 PRIORITY INFO.: 1994-P 44 36 696.5 19941013  
 DE 1994-P 44 36 696.5 19941013  
 DE 1994-P 44 45 562.3 19941220  
 DE 1994-P 44 45 562.3 19941220

L38 ANSWER 7 OF 8 PCTFULL COPYRIGHT 2005 Univentio on STN  
 ACCESSION NUMBER: 1993015761 PCTFULL ED 20020513  
 TITLE (ENGLISH): MALARIA TREATMENTS  
 TITLE (FRENCH): TRAITEMENTS DU PALUDISME  
 INVENTOR(S): PLAYFAIR, John, Hugh, Lyon;

PATENT ASSIGNEE(S):	TAVERNE, Janice; BATE, Clive, Alan, Winston UNIVERSITY COLLEGE LONDON; PLAYFAIR, John, Hugh, Lyon; TAVERNE, Janice; BATE, Clive, Alan, Winston		
LANGUAGE OF PUBL.:	English		
DOCUMENT TYPE:	Patent		
PATENT INFORMATION:			
	NUMBER	KIND	DATE
	-----		
	WO 9315761	A1	19930819
DESIGNATED STATES			
W:	AU BR CA JP KP KR LK MG RU SD US AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR SN TD TG		
APPLICATION INFO.:	WO 1993-GB84	A	19930115
PRIORITY INFO.:	1992-9203039.4		19920213
	GB 1992-9203039.4		19920213
L38 ANSWER 8 OF 8	PCTFULL COPYRIGHT 2005 Univentio on STN		
ACCESSION NUMBER:	1990012091 PCTFULL ED 20020513		
TITLE (ENGLISH):	UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR		
TITLE (FRENCH):	RECEPTEUR DE L'ACTIVATEUR DU PLASMINOGENE DU TYPE		
INVENTOR(S):	UROKINASE DANO, Keld; BLASI, Francesco; ROLDAN, Ann, Louring; CUBELLIS, Maria, Vittoria; MASUCCI, Maria, Teresa; APPELLA, Ettore; SCHLEUNING, W., D.; BEHRENDT, Niels; RONNE, Ebbe; KRISTENSEN, PETER; PoeLLAeNEN, Jari; SALONEN, Eeva-Marjatta; STEPHENS, Ross, W.; TAPIOVAARA, Hannele; VAHERI, Antii; MOLLER, Lisbeth, Birk; ELLIS, Vincent; LUND, Leif, Roge; PLOUG, Michael; PYKE, Charles; PATTHY, Laszlo		
PATENT ASSIGNEE(S):	CANCERFORSKNINGSFONDET AF 1989; DANO, Keld; BLASI, Francesco; ROLDAN, Ann, Louring; CUBELLIS, Maria, Vittoria; MASUCCI, Maria, Teresa; APPELLA, Ettore; SCHLEUNING, W., D.; BEHRENDT, Niels; RONNE, Ebbe; KRISTENSEN, PETER; PoeLLAeNEN, Jari; SALONEN, Eeva-Marjatta; STEPHENS, Ross, W.; TAPIOVAARA, Hannele; VAHERI, Antii; MOLLER, Lisbeth, Birk; ELLIS, Vincent;		

LUND, Leif, Roge;  
 PLOUG, Michael;  
 PYKE, Charles;  
 PATTHY, Laszlo  
 LANGUAGE OF PUBL.: English  
 DOCUMENT TYPE: Patent  
 PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9012091	A1	19901018

DESIGNATED STATES  
 W: AT AU BE BG BR CA CH DE DK ES FI FR GB HU IT JP KP KR  
 LK LU NL NO RO SE SU US  
 APPLICATION INFO.: WO 1990-DK90 A 19900409  
 PRIORITY INFO.: 1989-334,613 19890407  
 US 1989-334,613 19890407  
 US 1989-374,854 19890703  
 US 1989-374,854 19890703

=> d his

(FILE 'HOME' ENTERED AT 12:53:49 ON 16 MAR 2005)

FILE 'MEDLINE' ENTERED AT 12:54:02 ON 16 MAR 2005

L1 151259 S PHOSPHOL? OR PHOSPHATIDYL?  
 L2 682382 S ANTIBOD?  
 L3 1694388 S CANCER? OR TUMOR? OR NEOPLAS?  
 L4 11100 S L1 AND L2  
 L5 1564 S L3 AND L4  
 L6 101821 S L1/AB  
 L7 128238 S PHOSPHOLIPID? OR PHOSPHATIDYL?  
 L8 82550 S L7/AB  
 L9 2063 S L8 (S) L2  
 L10 168 S L9 AND L3  
 L11 111 S L10 NOT PY>1998  
 L12 4 S L11 AND VASCULA?

FILE 'CANCERLIT' ENTERED AT 12:59:15 ON 16 MAR 2005

L13 15945 S PHOSPHOLIPID? OR PHOSPHATIDYL?  
 L14 162627 S ANTIBOD?  
 L15 1284 S L13 (S) L14  
 L16 1221530 S CANCER? OR TUMOR? OR NEOPLAS?  
 L17 653 S L15 AND L16  
 L18 496 S L17 NOT PY>1998  
 L19 12 S L18 AND VASCULA?  
 L20 0 S L19 NOT L12

FILE 'STNGUIDE' ENTERED AT 13:02:22 ON 16 MAR 2005

FILE 'CANCERLIT' ENTERED AT 13:03:13 ON 16 MAR 2005

FILE 'STNGUIDE' ENTERED AT 13:03:13 ON 16 MAR 2005

FILE 'DISSABS' ENTERED AT 13:03:42 ON 16 MAR 2005

FILE 'CAPLUS' ENTERED AT 13:04:03 ON 16 MAR 2005

L21 90930 S PHOSPHATIDYL?  
 L22 67894 S L21/AB  
 L23 427880 S ANTIBOD?  
 L24 3952 S L22 AND L23  
 L25 368747 S L23/AB  
 L26 3660 S L25 AND L22  
 L27 635338 S CANCER? OR NEOPLAS? OR TUMOR?

L28 464 S L27 AND L26  
L29 206 S L28 NOT PY>1998  
L30 7 S L29 AND VASCULA?

FILE 'PCTFULL' ENTERED AT 13:07:31 ON 16 MAR 2005

L31 13823 S PHOSPHATIDYL?  
L32 322 S L31/AB  
L33 76152 S ANTIBOD?  
L34 14004 S L33/AB  
L35 28 S L34 AND L32  
L36 82019 S CANCER? OR NEOPALS? OR TUMOR?  
L37 19 S L36 AND L35  
L38 8 S L37 NOT PY>1998

=> d 119 ibib 7-12

YOU HAVE REQUESTED DATA FROM FILE 'CANCERLIT' - CONTINUE? (Y)/N:y

L19 ANSWER 7 OF 12 CANCERLIT on STN  
ACCESSION NUMBER: 94065586 CANCERLIT  
DOCUMENT NUMBER: 94065586 PubMed ID: 7504060  
TITLE: A critical role for monocytes and CD14 in endotoxin-induced endothelial cell activation.  
AUTHOR: Pugin J; Ulevitch R J; Tobias P S  
CORPORATE SOURCE: Department of Immunology, Scripps Research Institute, La Jolla, California 92037.  
CONTRACT NUMBER: AI-32021 (NIAID)  
GM-37696 (NIGMS)  
SOURCE: JOURNAL OF EXPERIMENTAL MEDICINE, (1993 Dec 1) 178 (6) 2193-200.  
Journal code: 2985109R. ISSN: 0022-1007.  
PUB. COUNTRY: United States  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: MEDLINE; Priority Journals  
OTHER SOURCE: MEDLINE 94065586  
ENTRY MONTH: 199312  
ENTRY DATE: Entered STN: 19941107  
Last Updated on STN: 19960517

L19 ANSWER 8 OF 12 CANCERLIT on STN  
ACCESSION NUMBER: 93112942 CANCERLIT  
DOCUMENT NUMBER: 93112942 PubMed ID: 7678062  
TITLE: Expression of integrins and examination of their adhesive function in normal and leukemic hematopoietic cells.  
AUTHOR: Liesveld J L; Winslow J M; Frediani K E; Ryan D H; Abboud C N  
CORPORATE SOURCE: Hematology Unit, University of Rochester Medical Center, NY 14642.  
CONTRACT NUMBER: CA-32737 (NCI)  
HL-18208 (NHLBI)  
K11 HL02385-01A1 (NHLBI)  
+  
SOURCE: BLOOD, (1993 Jan 1) 81 (1) 112-21.  
Journal code: 7603509. ISSN: 0006-4971.  
PUB. COUNTRY: United States  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: MEDLINE; Abridged Index Medicus Journals; Priority Journals  
OTHER SOURCE: MEDLINE 93112942  
ENTRY MONTH: 199302  
ENTRY DATE: Entered STN: 19941107  
Last Updated on STN: 19970509

L19 ANSWER 9 OF 12 CANCERLIT on STN  
ACCESSION NUMBER: 89097255 CANCERLIT  
DOCUMENT NUMBER: 89097255 PubMed ID: 2911352  
TITLE: The mucosal vascular addressin is a  
tissue-specific endothelial cell adhesion molecule for  
circulating lymphocytes.  
AUTHOR: Nakache M; Berg E L; Streeter P R; Butcher E C  
CORPORATE SOURCE: Department of Pathology, Stanford University, California  
94305.  
SOURCE: NATURE, (1989 Jan 12) 337 (6203) 179-81.  
Journal code: 0410462. ISSN: 0028-0836.  
PUB. COUNTRY: ENGLAND: United Kingdom  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: MEDLINE; Priority Journals  
OTHER SOURCE: MEDLINE 89097255  
ENTRY MONTH: 198902  
ENTRY DATE: Entered STN: 19941107  
Last Updated on STN: 19941107

L19 ANSWER 10 OF 12 CANCERLIT on STN  
ACCESSION NUMBER: 88331082 CANCERLIT  
DOCUMENT NUMBER: 88331082 PubMed ID: 3138247  
TITLE: Tumor necrosis factor and immune interferon act  
in concert to slow the lateral diffusion of proteins and  
lipids in human endothelial cell membranes.  
AUTHOR: Stolpen A H; Golan D E; Pober J S  
CORPORATE SOURCE: Department of Biological Chemistry and Molecular  
Pharmacology, Harvard Medical School, Boston, Massachusetts  
02115.  
CONTRACT NUMBER: GM 07753 (NIGMS)  
HL 32854 (NHLBI)  
HL 36003 (NHLBI)  
SOURCE: JOURNAL OF CELL BIOLOGY, (1988 Aug) 107 (2) 781-9.  
Journal code: 0375356. ISSN: 0021-9525.  
PUB. COUNTRY: United States  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: MEDLINE; Priority Journals  
OTHER SOURCE: MEDLINE 88331082  
ENTRY MONTH: 198810  
ENTRY DATE: Entered STN: 19941107  
Last Updated on STN: 19941107

L19 ANSWER 11 OF 12 CANCERLIT on STN  
ACCESSION NUMBER: 87192482 CANCERLIT  
DOCUMENT NUMBER: 87192482 PubMed ID: 2437001  
TITLE: Human hepatocellular carcinoma: cross-reactive and  
idiotypic antigens associated with malignant transformation  
of epithelial cells.  
AUTHOR: Wiedmann K H; Trejdosiewicz L K; Southgate J; Thomas H C  
SOURCE: HEPATOLOGY, (1987 May-Jun) 7 (3) 543-50.  
Journal code: 8302946. ISSN: 0270-9139.  
PUB. COUNTRY: United States  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: MEDLINE; Priority Journals  
OTHER SOURCE: MEDLINE 87192482  
ENTRY MONTH: 198706  
ENTRY DATE: Entered STN: 19941107  
Last Updated on STN: 19960517

L19 ANSWER 12 OF 12 CANCERLIT on STN

ACCESSION NUMBER: 76614630      CANCERLIT  
 DOCUMENT NUMBER: 76614630  
 TITLE: COMPLICATIONS OF LYMPHOGRAPHY. REPORT OF FIVE CASES.  
 AUTHOR: Poirier R; Locher C; Kleisbauer J P; Laval P  
 CORPORATE SOURCE: Hopital Michel Levy, 84, rue de Lodi, 13006 Marseille, France.  
 SOURCE: Sem Hop Paris, (1975) 51 (49) 3001-3008.  
 ISSN: 0037-1777.  
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
 LANGUAGE: French  
 FILE SEGMENT: Institute for Cell and Developmental Biology  
 ENTRY MONTH: 197609  
 ENTRY DATE: Entered STN: 19941107  
 Last Updated on STN: 19941107

=> d 119 ibib 1-6

YOU HAVE REQUESTED DATA FROM FILE 'CANCERLIT' - CONTINUE? (Y)/N:y

L19 ANSWER 1 OF 12      CANCERLIT on STN

ACCESSION NUMBER: 1999002666      CANCERLIT  
 DOCUMENT NUMBER: 99002666      PubMed ID: 9788617  
 TITLE: Infarction of solid Hodgkin's tumors in mice by antibody-directed targeting of tissue factor to tumor vasculature.  
 AUTHOR: Ran S; Gao B; Duffy S; Watkins L; Rote N; Thorpe P E  
 CORPORATE SOURCE: Hamon Center for Therapeutic Oncology Research and the Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas 75235, USA.  
 CONTRACT NUMBER: 1R01CA74951-01 (NCI)  
 5R01CA54168-05 (NCI)  
 SOURCE: CANCER RESEARCH, (1998 Oct 15) 58 (20) 4646-53.  
 Journal code: 2984705R. ISSN: 0008-5472.  
 PUB. COUNTRY: United States  
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
 LANGUAGE: English  
 FILE SEGMENT: MEDLINE; Priority Journals  
 OTHER SOURCE: MEDLINE 1999002666  
 ENTRY MONTH: 199811  
 ENTRY DATE: Entered STN: 19990122  
 Last Updated on STN: 19990122

L19 ANSWER 2 OF 12      CANCERLIT on STN

ACCESSION NUMBER: 1998416166      CANCERLIT  
 DOCUMENT NUMBER: 98416166      PubMed ID: 9743521  
 TITLE: Urokinase receptor (CD87) regulates leukocyte recruitment via beta 2 integrins in vivo.  
 AUTHOR: May A E; Kanse S M; Lund L R; Gisler R H; Imhof B A; Preissner K T  
 CORPORATE SOURCE: Haemostasis Research Unit, Max-Planck Institute, Kerckhoff-Klinik, D-61231 Bad Nauheim, Germany.  
 SOURCE: JOURNAL OF EXPERIMENTAL MEDICINE, (1998 Sep 21) 188 (6) 1029-37.  
 Journal code: 2985109R. ISSN: 0022-1007.  
 PUB. COUNTRY: United States  
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
 LANGUAGE: English  
 FILE SEGMENT: MEDLINE; Priority Journals  
 OTHER SOURCE: MEDLINE 1998416166  
 ENTRY MONTH: 199810  
 ENTRY DATE: Entered STN: 19981118  
 Last Updated on STN: 19981118



L19 ANSWER 3 OF 12 CANCERLIT on STN  
 ACCESSION NUMBER: 97612102 CANCERLIT  
 DOCUMENT NUMBER: 97612102  
 TITLE: Increase in vasculature in human breast cancer xenografts in nude mice treated with hexadecylphosphocholine (Meeting abstract).  
 AUTHOR: Safa O; Parkin S M; Bibby M C  
 CORPORATE SOURCE: Department of Biomedical Sciences, University of Bradford, Bradford, West Yorkshire, BD7 1DP, UK.  
 SOURCE: Br J Cancer, (1996) 73 (Suppl 26) 24.  
 ISSN: 0007-0920.  
 DOCUMENT TYPE: (MEETING ABSTRACTS)  
 LANGUAGE: English  
 FILE SEGMENT: Institute for Cell and Developmental Biology  
 ENTRY MONTH: 199706  
 ENTRY DATE: Entered STN: 19980417  
 Last Updated on STN: 19980417

L19 ANSWER 4 OF 12 CANCERLIT on STN  
 ACCESSION NUMBER: 97275152 CANCERLIT  
 DOCUMENT NUMBER: 97275152 PubMed ID: 9129046  
 TITLE: CD24, a mucin-type glycoprotein, is a ligand for P-selectin on human tumor cells.  
 AUTHOR: Aigner S; Sthoeger Z M; Fogel M; Weber E; Zarn J; Ruppert M; Zeller Y; Vestweber D; Stahel R; Sammar M; Altevogt P  
 CORPORATE SOURCE: Tumor Immunology Programme, German Cancer Research Center, Heidelberg.  
 SOURCE: BLOOD, (1997 May 1) 89 (9) 3385-95.  
 Journal code: 7603509. ISSN: 0006-4971.  
 PUB. COUNTRY: United States  
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
 LANGUAGE: English  
 FILE SEGMENT: MEDLINE; Abridged Index Medicus Journals; Priority Journals  
 OTHER SOURCE: MEDLINE 97275152  
 ENTRY MONTH: 199706  
 ENTRY DATE: Entered STN: 19970711  
 Last Updated on STN: 19970711

L19 ANSWER 5 OF 12 CANCERLIT on STN  
 ACCESSION NUMBER: 97064647 CANCERLIT  
 DOCUMENT NUMBER: 97064647 PubMed ID: 8908197  
 TITLE: Tumor cell-conditioned medium stimulates expression of the urokinase receptor in vascular endothelial cells.  
 AUTHOR: Seghezzi G; Marelli R; Mandriota S J; Nolli M L; Mazzieri R; Mignatti P  
 CORPORATE SOURCE: Dipartimento di Genetica e Microbiologia, Universita di Pavia, Italy.  
 SOURCE: JOURNAL OF CELLULAR PHYSIOLOGY, (1996 Nov) 169 (2) 300-8.  
 Journal code: 0050222. ISSN: 0021-9541.  
 PUB. COUNTRY: United States  
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
 LANGUAGE: English  
 FILE SEGMENT: MEDLINE; Priority Journals  
 OTHER SOURCE: MEDLINE 97064647  
 ENTRY MONTH: 199612  
 ENTRY DATE: Entered STN: 19970108  
 Last Updated on STN: 19970509

L19 ANSWER 6 OF 12 CANCERLIT on STN  
 ACCESSION NUMBER: 96625383 CANCERLIT  
 DOCUMENT NUMBER: 96625383  
 TITLE: In vivo targeting of liposomal drug carriers.

AUTHOR: Longman S A  
CORPORATE SOURCE: Univ. of British Columbia, Canada.  
SOURCE: Diss Abstr Int [B], (1995) 56 (4) 1998.  
ISSN: 0419-4217.  
DOCUMENT TYPE: (THESIS)  
LANGUAGE: English  
FILE SEGMENT: Institute for Cell and Developmental Biology  
ENTRY MONTH: 199606  
ENTRY DATE: Entered STN: 19970509  
Last Updated on STN: 19970509

=> d l19 kwic 6

YOU HAVE REQUESTED DATA FROM FILE 'CANCERLIT' - CONTINUE? (Y)/N:y

L19 ANSWER 6 OF 12 CANCERLIT on STN

AB . . . respectively, for doxorubicin-loaded SA-LUVs compared to protein-free liposomes or to conditions where the target cells were not pre-labeled with biotinylated antibody. In vivo targeting of drug-loaded SA-LUVs (injected intraperitoneally or intravenously) to P388 target cells was also achieved. Two procedures were. . . liver with a low pre-dose (2 mg/kg drug) of liposomal doxorubicin. The second involved the incorporation of a polyethylene glycol-modified phospholipid (PEG2000-DSPE) in SA-LUVs. It was shown that incorporation of up to 2 mol% PEG-PE in liposomes resulted in an improved. . . SA-LUVs, however, there was no further increase in passive targeting to the peritoneal cavity. The presence of an established P388 tumor in the peritoneal cavity markedly increased the passive targeting of SA-LUVs to that location. These results are of interest in terms of developing an understanding of the mechanism by which liposomes leave the vascular compartment. SA-LUVs incorporating 2 mol% PEG-PE were found to bind optimally to multilamellar vesicles that incorporated biotinoylaminohexanoyl DSPE (BAH-MLV). This. . . based on SA-LUVs injected intraperitoneally demonstrated a 17-fold and 8-fold increase in binding to BAH-MLVs in the peritoneal cavity of tumor-free and tumor-bearing animals, respectively, compared to non-targeted systems. The extent of targeting achieved under these conditions was comparable to that observed in vitro. SA-LUVs injected intravenously demonstrated a 5-fold increase in binding compared to both tumor-free and tumor-bearing animals. These studies were extended to a solid tumor model where it was shown that the presence of intratumorally injected BAH-MLVs promoted the accumulation of iv administered SA-LUVs. SA-LUVs injected intravenously into mice bearing subcutaneous Lewis lung tumors accumulated 2-fold greater in tumors that had been injected with BAH-MLVs than tumors injected with MLVs. (Full text available from University Microfilms International, Ann Arbor, MI, as Order Number AADAA-INN95358)

=> d his

(FILE 'HOME' ENTERED AT 12:53:49 ON 16 MAR 2005)

FILE 'MEDLINE' ENTERED AT 12:54:02 ON 16 MAR 2005

L1 151259 S PHOSPHOL? OR PHOSPHATIDYL?  
L2 682382 S ANTIBOD?  
L3 1694388 S CANCER? OR TUMOR? OR NEOPLAS?  
L4 11100 S L1 AND L2  
L5 1564 S L3 AND L4  
L6 101821 S L1/AB  
L7 128238 S PHOSPHOLIPID? OR PHOSPHATIDYL?  
L8 82550 S L7/AB

L9 2063 S L8 (S) L2  
L10 168 S L9 AND L3  
L11 111 S L10 NOT PY>1998  
L12 4 S L11 AND VASCULA?

FILE 'CANCERLIT' ENTERED AT 12:59:15 ON 16 MAR 2005

L13 15945 S PHOSPHOLIPID? OR PHOSPHATIDYL?  
L14 162627 S ANTIBOD?  
L15 1284 S L13 (S) L14  
L16 1221530 S CANCER? OR TUMOR? OR NEOPLAS?  
L17 653 S L15 AND L16  
L18 496 S L17 NOT PY>1998  
L19 12 S L18 AND VASCULA?  
L20 0 S L19 NOT L12

FILE 'STNGUIDE' ENTERED AT 13:02:22 ON 16 MAR 2005

FILE 'CANCERLIT' ENTERED AT 13:03:13 ON 16 MAR 2005

FILE 'STNGUIDE' ENTERED AT 13:03:13 ON 16 MAR 2005

FILE 'DISSABS' ENTERED AT 13:03:42 ON 16 MAR 2005

FILE 'CAPLUS' ENTERED AT 13:04:03 ON 16 MAR 2005

L21 90930 S PHOSPHATIDYL?  
L22 67894 S L21/AB  
L23 427880 S ANTIBOD?  
L24 3952 S L22 AND L23  
L25 368747 S L23/AB  
L26 3660 S L25 AND L22  
L27 635338 S CANCER? OR NEOPLAS? OR TUMOR?  
L28 464 S L27 AND L26  
L29 206 S L28 NOT PY>1998  
L30 7 S L29 AND VASCULA?

FILE 'PCTFULL' ENTERED AT 13:07:31 ON 16 MAR 2005

L31 13823 S PHOSPHATIDYL?  
L32 322 S L31/AB  
L33 76152 S ANTIBOD?  
L34 14004 S L33/AB  
L35 28 S L34 AND L32  
L36 82019 S CANCER? OR NEOPLAS? OR TUMOR?  
L37 19 S L36 AND L35  
L38 8 S L37 NOT PY>1998

FILE 'CANCERLIT' ENTERED AT 13:10:38 ON 16 MAR 2005

FILE 'PCTFULL' ENTERED AT 13:10:39 ON 16 MAR 2005

FILE 'CANCERLIT' ENTERED AT 13:11:09 ON 16 MAR 2005

FILE 'PCTFULL' ENTERED AT 13:11:10 ON 16 MAR 2005

FILE 'CANCERLIT' ENTERED AT 13:11:40 ON 16 MAR 2005

FILE 'PCTFULL' ENTERED AT 13:11:40 ON 16 MAR 2005

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	1.05	61.12
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-2.19

STN INTERNATIONAL LOGOFF AT 13:12:16 ON 16 MAR 2005

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1642BJF

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1	Web Page URLs for STN Seminar Schedule - N. America
NEWS 2	"Ask CAS" for self-help around the clock
NEWS 3 FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS 4 APR 04	STN AnaVist \$500 visualization usage credit offered
NEWS 5 MAY 10	CA/CAPLUS enhanced with 1900-1906 U.S. patent records
NEWS 6 MAY 11	KOREAPAT updates resume
NEWS 7 MAY 19	Derwent World Patents Index to be reloaded and enhanced
NEWS 8 MAY 30	IPC 8 Rolled-up Core codes added to CA/CAPLUS and USPATFULL/USPAT2
NEWS 9 MAY 30	The F-Term thesaurus is now available in CA/CAPLUS
NEWS 10 JUN 02	The first reclassification of IPC codes now complete in INPADOC
NEWS 11 JUN 26	TULSA/TULSA2 reloaded and enhanced with new search and and display fields
NEWS 12 JUN 28	Price changes in full-text patent databases EPFULL and PCTFULL
NEWS 13 JUL 11	CHEMSAFE reloaded and enhanced
NEWS 14 JUL 14	FSTA enhanced with Japanese patents
NEWS 15 JUL 19	Coverage of Research Disclosure reinstated in DWPI
NEWS EXPRESS	JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8
NEWS X25	X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer

agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 08:37:04 ON 07 AUG 2006

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 08:37:14 ON 07 AUG 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 4 AUG 2006 HIGHEST RN 898908-64-0

DICTIONARY FILE UPDATES: 4 AUG 2006 HIGHEST RN 898908-64-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> E "BETA 2 GLYCOPROTEIN"/CN 25

E1 1 BETA 1,4 GLUCOSYLTRANSFERASE (XYLELLA FASTIDIOSA STRAIN TEMECULA1 GENE PD0815)/CN  
E2 1 BETA 2/CN  
E3 0 --> BETA 2 GLYCOPROTEIN/CN  
E4 1 BETA 2-MICROGLOBULIN (HUMAN CELL LINE HELA)/CN  
E5 1 BETA 2-MICROGLOBULIN (HUMAN GENE &LT;BETA&GT;2-&LT;MU&GT;)/CN  
E6 1 BETA 21S/CN  
E7 1 BETA 3/CN  
E8 1 BETA 3-ENDONEXIN SHORT FORM (HUMAN)/CN  
E9 1 BETA 3-GLYCOSYLTRANSFERASE-LIKE (HUMAN CLONE MGC:87629 IMAGE:4837250)/CN  
E10 1 BETA 4 ADDUCIN (HUMAN)/CN  
E11 1 BETA 4 NICOTINIC ACETYLCHOLINE RECEPTOR SUBUNIT (HUMAN)/CN  
E12 1 BETA 5-TUBULIN (HUMAN CLONE MGC:15683 IMAGE:3350604)/CN  
E13 1 BETA 5-TUBULIN (HUMAN CLONE MGC:15853 IMAGE:3509417)/CN  
E14 1 BETA 5-TUBULIN (HUMAN CLONE MGC:16435 IMAGE:3946253)/CN  
E15 1 BETA 5-TUBULIN (HUMAN CLONE MGC:2440 IMAGE:2820585)/CN  
E16 1 BETA 5-TUBULIN (HUMAN CLONE MGC:26663 IMAGE:4795692)/CN  
E17 1 BETA 5-TUBULIN (HUMAN CLONE MGC:30201 IMAGE:4998571)/CN  
E18 1 BETA 5-TUBULIN (HUMAN CLONE MGC:4101 IMAGE:2820585)/CN  
E19 1 BETA 5-TUBULIN (HUMAN CLONE MGC:8668 IMAGE:2964461)/CN  
E20 1 BETA 5-TUBULIN (HUMAN CLONE MGC:88329 IMAGE:6698679)/CN  
E21 1 BETA 850/CN  
E22 1 BETA A3/A1 CRYSTALLIN (HUMAN GENE CYRBA3/A1)/CN

E23	2	BETA A4 CRYSTALLIN (HUMAN GENE CRYBA4)/CN
E24	1	BETA ACTIN (HUMAN CLONE MGC:10559 IMAGE:3623067)/CN
E25	1	BETA ACTIN (HUMAN CLONE MGC:16525 IMAGE:4025526)/CN

=> E "APOLIPOPROTEIN"/CN 25

E1	1	APOLIPOPHORIN-III (SOLENOPTIS INVICTA C-TERMINAL FRAGMENT)/CN
E2	1	APOLIPOPOPROTEINASE (STREPTOCOCCUS PYOGENES STRAIN D734 GENE SOF22)/CN
E3	0	--> APOLIPOPROTEIN/CN
E4	1	APOLIPOPROTEIN (ANGUILLA JAPONICA LIVER ISOFORM 14KDA PRECURSOR)/CN
E5	1	APOLIPOPROTEIN (ANGUILLA JAPONICA LIVER ISOFORM 28KDA-1A PRECURSOR)/CN
E6	1	APOLIPOPROTEIN (ANGUILLA JAPONICA LIVER ISOFORM 28KDA-1B PRECURSOR)/CN
E7	1	APOLIPOPROTEIN (ANGUILLA JAPONICA LIVER ISOFORM 28KDA-1C PRECURSOR)/CN
E8	1	APOLIPOPROTEIN (ANGUILLA JAPONICA LIVER ISOFORM 28KDA-1D PRECURSOR)/CN
E9	1	APOLIPOPROTEIN (ANGUILLA JAPONICA LIVER ISOFORM 28KDA-1E PRECURSOR)/CN
E10	1	APOLIPOPROTEIN (ANGUILLA JAPONICA LIVER ISOFORM 28KDA-2 PRECURSOR)/CN
E11	1	APOLIPOPROTEIN (CARASSIUS AURATUS GIBELIO)/CN
E12	1	APOLIPOPROTEIN (CORYNEBACTERIUM MATRUCHOTII STRAIN ATCC-14266 CALCIUM-PRECIPIITATING 5.0-KILODALTON)/CN
E13	1	APOLIPOPROTEIN (CORYNEBACTERIUM MATRUCHOTII STRAIN ATCC-14266 CALCIUM-PRECIPIITATING 5.5-KILODALTON)/CN
E14	1	APOLIPOPROTEIN (ESCHERICHIA COLI O157:H7 STRAIN EDL933 GENE YABC)/CN
E15	1	APOLIPOPROTEIN (ESCHERICHIA COLI STRAIN O157:H7 GENE ECS0086)/CN
E16	1	APOLIPOPROTEIN (HUMAN C-TERMINAL DOMAIN)/CN
E17	1	APOLIPOPROTEIN (HUMAN CLONE BAC_201G24 GENE APOM)/CN
E18	1	APOLIPOPROTEIN (HUMAN GENE APOC4)/CN
E19	1	APOLIPOPROTEIN (HUMAN)/CN
E20	1	APOLIPOPROTEIN (MYCOPLASMA AGALACTIAE STRAIN 627#3 GENE AVGA)/CN
E21	1	APOLIPOPROTEIN (MYCOPLASMA AGALACTIAE STRAIN 627#3 GENE AVGB)/CN
E22	1	APOLIPOPROTEIN (MYCOPLASMA AGALACTIAE STRAIN 627#3 GENE AVGC)/CN
E23	1	APOLIPOPROTEIN (MYCOPLASMA AGALACTIAE STRAIN 627#3 GENE AVGD)/CN
E24	1	APOLIPOPROTEIN (MYCOPLASMA AGALACTIAE STRAIN 627#3 GENE AVGE)/CN
E25	1	APOLIPOPROTEIN (MYCOPLASMA AGALACTIAE STRAIN 627#3 GENE AVGF)/CN

=> E "GLYCOPROTEIN 1"/CN 25

E1	1	GLYCOPROTEIN Σ1 (REOVIRUS 3 PROTEIN MOIETY)/CN
E2	1	GLYCOPROTEIN Σ2 (HUMAN REOVIRUS 1 STRAIN LANG ATCC VR-230 PROTEIN MOIETY REDUCED)/CN
E3	0	--> GLYCOPROTEIN 1/CN
E4	1	GLYCOPROTEIN 1 (JUNIN VIRUS STRAIN CBAAN9446 GENE G1 C-TERMINAL FRAGMENT)/CN
E5	1	GLYCOPROTEIN 1 (JUNIN VIRUS STRAIN CBALYE63 GENE G1 C-TERMINAL FRAGMENT)/CN
E6	1	GLYCOPROTEIN 1 (JUNIN VIRUS STRAIN PAN14661 GENE G1 C-TERMINAL FRAGMENT)/CN
E7	1	GLYCOPROTEIN 1 (JUNIN VIRUS STRAIN PAN16288 GENE G1 C-TERMINAL FRAGMENT)/CN
E8	1	GLYCOPROTEIN 1 (JUNIN VIRUS STRAIN PAN19107 GENE G1 C-TERMINAL FRAGMENT)/CN
E9	1	GLYCOPROTEIN 1 (JUNIN VIRUS STRAIN PAN19109 GENE G1 C-TERMINAL FRAGMENT)/CN
E10	1	GLYCOPROTEIN 1 (JUNIN VIRUS STRAIN PAN19221 GENE G1 C-TERMINAL FRAGMENT)/CN
E11	1	GLYCOPROTEIN 1 (JUNIN VIRUS STRAIN PAN9918 GENE G1 C-TERMINAL FRAGMENT)/CN
E12	1	GLYCOPROTEIN 1 (JUNIN VIRUS STRAIN PH3190 GENE G1 C-TERMINAL FRAGMENT)/CN

E13	1	GLYCOPROTEIN 1 (JUNIN VIRUS STRAIN PH3878 GENE G1 C-TERMINAL
FRAGMENT) /CN		
E14	1	GLYCOPROTEIN 1 (JUNIN VIRUS STRAIN PH4757 GENE G1 C-TERMINAL
FRAGMENT) /CN		
E15	1	GLYCOPROTEIN 1 (JUNIN VIRUS STRAIN PH4795 GENE G1 C-TERMINAL
FRAGMENT) /CN		
E16	1	GLYCOPROTEIN 1 (JUNIN VIRUS STRAIN PH4906 GENE G1 C-TERMINAL
FRAGMENT) /CN		
E17	1	GLYCOPROTEIN 1 (JUNIN VIRUS STRAIN PH5949 GENE G1 C-TERMINAL
FRAGMENT) /CN		
E18	1	GLYCOPROTEIN 1 (JUNIN VIRUS STRAIN PH6699 GENE G1 C-TERMINAL
FRAGMENT) /CN		
E19	1	GLYCOPROTEIN 1 (JUNIN VIRUS STRAIN PH7994 GENE G1 C-TERMINAL
FRAGMENT) /CN		
E20	1	GLYCOPROTEIN 1 (JUNIN VIRUS STRAIN PH8845 GENE G1 C-TERMINAL
FRAGMENT) /CN		
E21	1	GLYCOPROTEIN 1 (JUNIN VIRUS STRAIN PHTOLEDO GENE G1 C-TERMINAL
FRAGMENT) /CN		
E22	1	GLYCOPROTEIN 1 (JUNIN VIRUS STRAIN XJ44 GENE G1 C-TERMINAL
FRAGMENT) /CN		
E23	1	GLYCOPROTEIN 1 (JUNIN VIRUS STRAIN XJCL3 GENE G1 C-TERMINAL
FRAGMENT) /CN		
E24	1	GLYCOPROTEIN 1 (MYCOBACTERIUM PHAGE TM4) /CN
E25	1	GLYCOPROTEIN 10 (HUMAN STOMACH CANCER CELL LINE KATO-II CLONE
AKP10) /CN		

=> E "2-GLYCOPROTEIN 1"/CN 25

E1	1	2-GLYCINE-5-ISOLEUCINE-ANGIOTENSIN II AMIDE/CN
E2	1	2-GLYCINE-LUTEINIZING HORMONE-RELEASING FACTOR (PIG) /CN
E3	0 -->	2-GLYCOPROTEIN 1/CN
E4	1	2-GLYCYL (METHYL) AMINO-5-CHLOROBENZOPHENONE/CN
E5	1	2-GLYCYLAMINO-5-NITROBENZOPHENONE/CN
E6	1	2-GLYOXYLAMIDO-1-METHYLPYRIDINIUM IODIDE, OXIME/CN
E7	1	2-GUAIACOXYETHANOL/CN
E8	1	2-GUAIACYL-1,3-PROPANEDIOL/CN
E9	1	2-GUAIACYL-5- (2'-GUAIACYLETHYL) TETRAHYDROFURAN/CN
E10	1	2-GUANDINO-4- (3-NITROPHENYL) THIAZOLE/CN
E11	1	2-GUANIDINECARBOXYLIC ACID, 1,1,3,3-TETRAPHENYL-/CN
E12	1	2-GUANIDINO-3-MERCAPTOPROPIONIC ACID/CN
E13	1	2-GUANIDINO-4- ( (2-AMINOETHYL) THIOMETHYL) THIAZOLE/CN
E14	1	2-GUANIDINO-4- (4-IMIDAZOLYL) THIAZOLE/CN
E15	1	2-GUANIDINO-4- (HYDROXYMETHYL) THIAZOLE/CN
E16	1	2-GUANIDINO-4-CHLORO-6-METHYLPYRIMIDINE SULFATE/CN
E17	1	2-GUANIDINO-4-METHYL-7,8-DIHYDRO-5H-PYRIDO (4,3-D) PYRIMIDINE-6-CARBOXYLIC ACID
		TERT-BUTYL ESTER/CN
E18	1	2-GUANIDINO-4-METHYLQUINAZOLINE/CN
E19	1	2-GUANIDINO-5-METHYLBENZIMIDAZOLE/CN
E20	1	2-GUANIDINO-6,7-DIHYDRO-4H-THIAZOLO (5,4-C) PYRIDIN-5-CARBOXYLIC
		ACID TERT-BUTYL ESTER/CN
E21	1	2-GUANIDINO-N- (2- (5-METHOXY-2-METHYL-1H-INDOL-3-YL) ETHYL) -N- (3,4,5-TRIMETHOXYBENZYL)
		ACETAMIDE/CN
E22	1	2-GUANIDINO-N- (4- (1H-INDOL-3-YL) BUTYL) -N- (3,4,5-TRIMETHOXYBENZYL) ACETAMIDE/CN
E23	1	2-GUANIDINO-N-INDAN-2-YL-N- (1H-INDOL-3-YLMETHYL) ACETAMIDE/CN
E24	1	2-GUANIDINO BENZIMIDAZOLE/CN
E25	1	2-GUANIDINO BENZOTHIAZOLE/CN

=> file medline

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

1.32

1.53

FILE 'MEDLINE' ENTERED AT 08:38:46 ON 07 AUG 2006

FILE LAST UPDATED: 5 Aug 2006 (20060805/UP). FILE COVERS 1950 TO DATE.

On December 11, 2005, the 2006 MeSH terms were loaded.

The MEDLINE reload for 2006 is now (26 Feb.) available. For details on the 2006 reload, enter HELP RLOAD at an arrow prompt (=>).

See also:

<http://www.nlm.nih.gov/mesh/>  
[http://www.nlm.nih.gov/pubs/techbull/nd04/nd04\\_mesh.html](http://www.nlm.nih.gov/pubs/techbull/nd04/nd04_mesh.html)  
[http://www.nlm.nih.gov/pubs/techbull/nd05/nd05\\_med\\_data\\_changes.html](http://www.nlm.nih.gov/pubs/techbull/nd05/nd05_med_data_changes.html)  
[http://www.nlm.nih.gov/pubs/techbull/nd05/nd05\\_2006\\_MeSH.html](http://www.nlm.nih.gov/pubs/techbull/nd05/nd05_2006_MeSH.html)

OLDMEDLINE is covered back to 1950.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2006 vocabulary.

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s beta-2-glycoprotein-1
      552518 BETA
      591 BETAS
      552629 BETA
            (BETA OR BETAS)
      3327525 2
      80084 GLYCOPROTEIN
      121789 GLYCOPROTEINS
      170931 GLYCOPROTEIN
            (GLYCOPROTEIN OR GLYCOPROTEINS)
      3790432 1
L1      89 BETA-2-GLYCOPROTEIN-1
            (BETA(W)2(W)GLYCOPROTEIN(W)1)
```

=> d kwic

```
L1      ANSWER 1 OF 89      MEDLINE on STN
AB      . . . based on the occurrence of cardiopulmonary embolism in the child
      with a high titre of autoantibodies directed against phospholipids and
      beta-2-glycoprotein 1. In spite of
      a relatively rapid diagnosis and multiple treatments, the outcome was
      unfavourable. Multimodality imaging, including both ultrasonography and.
      . .
```

```
=> s cancer? or tumor? or neoplas?
      579286 CANCER?
      805283 TUMOR?
      1512132 NEOPLAS?
L2      1833409 CANCER? OR TUMOR? OR NEOPLAS?
```

```
=> s l2 and l1
L3      0 L2 AND L1
```

=> file pctfull  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.83	2.36

FULL ESTIMATED COST

FILE 'PCTFULL' ENTERED AT 08:39:55 ON 07 AUG 2006  
COPYRIGHT (C) 2006 Univentio



FILE LAST UPDATED: 31 JUL 2006 <20060731/UP>  
MOST RECENT UPDATE WEEK: 200630 <200630/EW>  
FILE COVERS 1978 TO DATE

>>> IMAGES ARE AVAILABLE ONLINE AND FOR EMAIL-PRINTS <<<

>>> NEW IPC8 DATA AND FUNCTIONALITY NOW AVAILABLE IN THIS FILE.

SEE

<http://www.stn-international.de/stndatabases/details/ipc-reform.html> >>>

>>> FOR CHANGES IN PCTFULL PLEASE SEE HELP CHANGE

(last updated April 10, 2006) <<<

>>> NEW PRICES IN PCTFULL AS OF 01 JULY 2006. FOR DETAILS,  
PLEASE SEE HELP COST <<<

=> s (beta-2-glycoprotein) or (beta 2 glycoprotein)

80476 BETA

299 BETAS

80529 BETA

(BETA OR BETAS)

1033161 2

20890 GLYCOPROTEIN

13512 GLYCOPROTEINS

27572 GLYCOPROTEIN

(GLYCOPROTEIN OR GLYCOPROTEINS)

59 BETA-2-GLYCOPROTEIN

(BETA(W) 2 (W) GLYCOPROTEIN)

80476 BETA

299 BETAS

80529 BETA

(BETA OR BETAS)

1033161 2

20890 GLYCOPROTEIN

13512 GLYCOPROTEINS

27572 GLYCOPROTEIN

(GLYCOPROTEIN OR GLYCOPROTEINS)

59 BETA 2 GLYCOPROTEIN

(BETA(W) 2 (W) GLYCOPROTEIN)

L4

59 (BETA-2-GLYCOPROTEIN) OR (BETA 2 GLYCOPROTEIN)

=> s 14/ab

9806 BETA/AB

9 BETAS/AB

9808 BETA/AB

((BETA OR BETAS)/AB)

211867 2/AB

881 GLYCOPROTEIN/AB

312 GLYCOPROTEINS/AB

1118 GLYCOPROTEIN/AB

((GLYCOPROTEIN OR GLYCOPROTEINS)/AB)

8 BETA-2-GLYCOPROTEIN/AB

((BETA(W) 2 (W) GLYCOPROTEIN)/AB)

9806 BETA/AB

9 BETAS/AB

9808 BETA/AB

((BETA OR BETAS)/AB)

211867 2/AB

881 GLYCOPROTEIN/AB

312 GLYCOPROTEINS/AB

1118 GLYCOPROTEIN/AB

((GLYCOPROTEIN OR GLYCOPROTEINS)/AB)

8 BETA 2 GLYCOPROTEIN/AB

((BETA(W)2(W)GLYCOPROTEIN)/AB)  
L5 8 ((BETA-2-GLYCOPROTEIN/AB) OR (BETA 2 GLYCOPROTEIN/AB))

=> s cancer? or tumor? or neoplas?

80252 CANCER?  
66950 TUMOR?  
23264 NEOPLAS?

L6 99855 CANCER? OR TUMOR? OR NEOPLAS?

=> s l5 and l6

L7 3 L5 AND L6

=> d ibib 1-3

L7 ANSWER 1 OF 3 PCTFULL COPYRIGHT 2006 Univentio on STN  
ACCESSION NUMBER: 2003099833 PCTFULL ED 20031215 EW 200349  
TITLE (ENGLISH): BETA-2-GLYCOPROTEIN 1 IS AN INHIBITOR OF ANGIOGENESIS  
TITLE (FRENCH): LA BETA-2-GLYCOPROTEINE 1 EST UN INHIBITEUR DE  
L'ANGIOGENESE  
INVENTOR(S): SCHROIT, Alan, Jay, 4619 Willow Street, Bellaire, TX  
77401, US [US, US];  
BALASUBRAMANIAN, Krishnakumar, 2601 Sunday house court,  
Pearland, TX 77584, US [IN, US];  
MCCARTY, Marya, F., 2255 Braeswood Park Drive, #121,  
Bellaire, TX 77030, US [US, US]  
PATENT ASSIGNEE(S): BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, 201  
West 7th Street, Suite 820, Austin, TX 78701, US [US,  
US], for all designates States except US;  
SCHROIT, Alan, Jay, 4619 Willow Street, Bellaire, TX  
77401, US [US, US], for US only;  
BALASUBRAMANIAN, Krishnakumar, 2601 Sunday house court,  
Pearland, TX 77584, US [IN, US], for US only;  
MCCARTY, Marya, F., 2255 Braeswood Park Drive, #121,  
Bellaire, TX 77030, US [US, US], for US only  
AGENT: SAMPSON, Margaret, J.\$, Vinson & Elkins L.L.P., 2300  
First City Tower, 1001 Fannin Street, Houston, TX  
77002-6760\$, US  
LANGUAGE OF FILING: English  
LANGUAGE OF PUBL.: English  
DOCUMENT TYPE: Patent  
PATENT INFORMATION:

NUMBER	KIND	DATE
-----		
WO 2003099833	A2	20031204

DESIGNATED STATES

W:

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR  
CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID  
IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD  
MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SD SE SG  
SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

RW (ARIPO):

GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW

RW (EAPO):

AM AZ BY KG KZ MD RU TJ TM

RW (EPO):

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU  
MC NL PT RO SE SI SK TR

RW (OAPI):

BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

APPLICATION INFO.:

WO 2003-US10188 A 20030402

PRIORITY INFO.:

US 2002-60/381,219 20020517

L7 ANSWER 2 OF 3

PCTFULL COPYRIGHT 2006 Univentio on STN

ACCESSION NUMBER:

2001018541 PCTFULL ED 20020828

TITLE (ENGLISH):

USE OF BETA2GPI IN DIAGNOSTIC TESTS FOR AUTOIMMUNE  
DISEASES

TITLE (FRENCH):

UTILISATION DE LA PROTEINE &beta;2GPI DANS DES TESTS  
DIAGNOSTIQUES POUR LES MALADIES AUTO-IMMUNES

INVENTOR(S): GECZY, Carolyn;  
MCNEIL, Hugh, Patrick;  
VISVANATHAN, Sudha  
PATENT ASSIGNEE(S): PSIRON LIMITED;  
GECZY, Carolyn;  
MCNEIL, Hugh, Patrick;  
VISVANATHAN, Sudha  
DOCUMENT TYPE: Patent  
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2001018541	A1	20010315

DESIGNATED STATES

W:

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU  
CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN  
IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK  
MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM  
TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD  
SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY  
DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG  
CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.:

WO 2000-AU1068 A 20000908

PRIORITY INFO.:

AU 1999-PQ 2726 19990909

L7 ANSWER 3 OF 3

PCTFULL COPYRIGHT 2006 Univentio on STN

ACCESSION NUMBER:

1996004006 PCTFULL ED 20020514

TITLE (ENGLISH):

USE OF AT LEAST ONE FORM OF THE 'beta'2-GLYCOPROTEIN I  
AS AN ANTI-INFECTIOUS AGENT AND PHARMACEUTICAL  
COMPOSITION CONTAINING SAME

TITLE (FRENCH):

UTILISATION DE LA 'beta'2-GLYCOPROTEINE I SOUS AU MOINS  
UNE DE SES FORMES COMME AGENT ANTI-INFECTIEUX ET  
COMPOSITION PHARMACEUTIQUE CORRESPONDANTE

INVENTOR(S):

STEFAS, Elie;  
RUCHETON, Marcel;  
GRAAFLAND, Hubert;  
VEAS, Francisco

PATENT ASSIGNEE(S):

INSTITUT FRANCAIS DE RECHERCHES SCIENTIFIQUES POUR LE  
DEVELOPPEMENT EN COOPERATION- ORSTOM;  
STEFAS, Elie;  
RUCHETON, Marcel;  
GRAAFLAND, Hubert;  
VEAS, Francisco

LANGUAGE OF PUBL.:

English

DOCUMENT TYPE:

Patent

PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9604006	A1	19960215

DESIGNATED STATES

W:

JP US AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

APPLICATION INFO.:

WO 1995-FR1030 A 19950731

PRIORITY INFO.:

FR 1994-94/09527 19940801

=> d kwic 3

L7 ANSWER 3 OF 3

PCTFULL COPYRIGHT 2006 Univentio on STN

ABEN

Use of the 'beta'2-glycoprotein I, in at  
least one of its forms, for producing an  
anti-infectious agent for treating infectious diseases and capable of.

DETD

. . . la Malaria, les  
phospholipides libErEs par le Plasmodium auraient une action toxique

hypoglycEmiante et seraient capable d'induire la libération par les  
macrophages de `tumor necrosis factor (TNF). La  
82'-glycoprotéine I  
est susceptible de lier ces phospholipides, inhibant leur nocivité  
(TAYLOR et autres, Clin. Exp. Immunol.. . .

=> s aminophospholipid?

L8 123 AMINOPHOSPHOLIPID?

=> s phosphatidylserine or phosphatididyleth?

3086 PHOSPHATIDYLSERINE

345 PHOSPHATIDYLSERINES

3277 PHOSPHATIDYLSERINE

(PHOSPHATIDYLSERINE OR PHOSPHATIDYLSERINES)

1 PHOSPHATIDIDYLETH?

L9 3278 PHOSPHATIDYLSERINE OR PHOSPHATIDIDYLETH?

=> d his

(FILE 'HOME' ENTERED AT 08:37:04 ON 07 AUG 2006)

FILE 'REGISTRY' ENTERED AT 08:37:14 ON 07 AUG 2006

E "BETA 2 GLYCOPROTEIN"/CN 25

E "APOLIPOPROTEIN"/CN 25

E "GLYCOPROTEIN 1"/CN 25

E "2-GLYCOPROTEIN 1"/CN 25

FILE 'MEDLINE' ENTERED AT 08:38:46 ON 07 AUG 2006

L1 89 S BETA-2-GLYCOPROTEIN-1

L2 1833409 S CANCER? OR TUMOR? OR NEOPLAS?

L3 0 S L2 AND L1

FILE 'PCTFULL' ENTERED AT 08:39:55 ON 07 AUG 2006

L4 59 S (BETA-2-GLYCOPROTEIN) OR (BETA 2 GLYCOPROTEIN)

L5 8 S L4/AB

L6 99855 S CANCER? OR TUMOR? OR NEOPLAS?

L7 3 S L5 AND L6

L8 123 S AMINOPHOSPHOLIPID?

L9 3278 S PHOSPHATIDYLSERINE OR PHOSPHATIDIDYLETH?

=> s 19 and 16

L10 2328 L9 AND L6

=> s antibod?

L11 89879 ANTIBOD?

=> s 110 and 111

L12 1874 L10 AND L11

=> s 16/clm.

'CLM.' IS NOT A VALID FIELD CODE

0 CANCER?/CLM.

0 TUMOR?/CLM.

0 NEOPLAS?/CLM.

L13 0 (CANCER?/CLM. OR TUMOR?/CLM. OR NEOPLAS?/CLM.)

=> s 16/clm

23069 CANCER?/CLM

15574 TUMOR?/CLM

3784 NEOPLAS?/CLM

L14 32790 (CANCER?/CLM OR TUMOR?/CLM OR NEOPLAS?/CLM)

=> s 114 and 112

L15 874 L14 AND L12

=> s 19/ab

62 PHOSPHATIDYL SERINE/AB  
6 PHOSPHATIDYL SERINES/AB  
66 PHOSPHATIDYL SERINE/AB  
((PHOSPHATIDYL SERINE OR PHOSPHATIDYL SERINES)/AB)  
0 PHOSPHATIDIDYLETH?/AB

L16 66 (PHOSPHATIDYL SERINE/AB OR PHOSPHATIDIDYLETH?/AB)

=> s l16 and l15

L17 15 L16 AND L15

=> s l17 not py>1998

776694 PY>1998

L18 1 L17 NOT PY>1998

=> d ibib

L18 ANSWER 1 OF 1 PCTFULL COPYRIGHT 2006 Univentio on STN  
ACCESSION NUMBER: 1989006977 PCTFULL ED 20020513  
TITLE (ENGLISH): FORMULATION AND USE OF RETINOIDS IN TREATMENT OF  
CANCER AND OTHER DISEASES  
TITLE (FRENCH): FORMULATION ET UTILISATION DE RETINOIDES DANS LE  
TRAITEMENT DU CANCER ET D'AUTRES MALADIES  
INVENTOR(S): MEHTA, Kapil;  
PEREZ-SOLER, Roman;  
LOPEZ-BERESTEIN, Gabriel  
PATENT ASSIGNEE(S): BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM  
LANGUAGE OF PUBL.: English  
DOCUMENT TYPE: Patent  
PATENT INFORMATION:

NUMBER	KIND	DATE
-----		
WO 8906977	A1	19890810

DESIGNATED STATES

W:

AT AU BB BE BG BJ BR CF CG CH CM DE DK FI FR GA GB HU  
IT JP KP KR LK LU MC MG ML MR MW NL NO RO SD SE SN SU  
TD TG

APPLICATION INFO.: WO 1989-US435 A 19890203  
PRIORITY INFO.: US 1988-152,183 19880204

=> d ibib kwic

L18 ANSWER 1 OF 1 PCTFULL COPYRIGHT 2006 Univentio on STN  
ACCESSION NUMBER: 1989006977 PCTFULL ED 20020513  
TITLE (ENGLISH): FORMULATION AND USE OF RETINOIDS IN TREATMENT OF  
CANCER AND OTHER DISEASES  
TITLE (FRENCH): FORMULATION ET UTILISATION DE RETINOIDES DANS LE  
TRAITEMENT DU CANCER ET D'AUTRES MALADIES  
INVENTOR(S): MEHTA, Kapil;  
PEREZ-SOLER, Roman;  
LOPEZ-BERESTEIN, Gabriel  
PATENT ASSIGNEE(S): BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM  
LANGUAGE OF PUBL.: English  
DOCUMENT TYPE: Patent  
PATENT INFORMATION:

NUMBER	KIND	DATE
-----		
WO 8906977	A1	19890810

DESIGNATED STATES

W:

AT AU BB BE BG BJ BR CF CG CH CM DE DK FI FR GA GB HU  
IT JP KP KR LK LU MC MG ML MR MW NL NO RO SD SE SN SU

TD TG

APPLICATION INFO.: WO 1989-US435 A 19890203

PRIORITY INFO.: US 1988-152,183 19880204

TIEN FORMULATION AND USE OF RETINOIDS IN TREATMENT OF CANCER AND OTHER DISEASES

TIFR FORMULATION ET UTILISATION DE RETINOIDES DANS LE TRAITEMENT DU CANCER ET D'AUTRES MALADIES

ABEN . . . animal, said quantity containing a therapeutically effective amount of the retinoid. The animal being administered the liposomes may bear a tumor impeded by retinoids and the administering step serve to impede growth of said tumor. The most preferred retinoid is all-trans retinoic acid although other retinoids may prove useful. In certain cases, the retinoid may be retinol, particularly all trans-retinol. The phospholipids of the present invention may be one or more of phosphatidylcholine, phosphatidylserine, phosphatidylglycerol, sphingomyelin and phosphatidic acid. These phospholipids, their derivatives and those of analogous structure and hydrophobic properties may be used. . .

ABFR . . . peut etre du retinol, notamment de l'allo trans-retinol. Les phospholipides de la presente invention peuvent etre un ou plusieurs phosphatidylcholines, phosphatidylserines, phosphatidylglycerols, sphingomyelines et acides phosphatidiques. On peut utiliser ces phospholipides, leurs derives et ceux de structure et de proprietes hydrophobes. . .

DETD FORMULATION AND USE OF RETINOIDS IN TREATMENT OF CANCER AND OTHER DISEASES

The present invention relates to therapeutic usage of retinoids encapsulated in liposomes.

. . . 1925). Several studies have shown that retinoids can suppress the process of carcinogenesis in vivo in experimental animals (for reviews, see e.g., Bollag, Cancer Chemother, Pharmacol., 3:207-215, 1979, and Sporn et al., In Zedeck et al. (eds.), Inhibition of Tumor induction and development, pp. 71-100, New York: Plenum Publishing Corp., 1981). These results are now the basis of current attempts to use retinoids for cancer prevention in humans. Furthermore, there is an extensive evidence which suggests that retinoids can suppress the development of malignant phenotype in vitro (for review, see e.g., Bertram et al., In: M.S. Arnott et al. (eds.), Molecular interactions of nutrition and cancer, pp 315 New York, Raven Press, 1982; Lotan et al., The modulation and mediation of cancer by vitamins, pp 211 Basel: S.

Karger AG, 1983) thus suggesting a potential use of 5 retinoids in cancer prevention. Also, recently it has been shown that retinoids can exert effects on certain fully transformed, invasive, neoplastic cells leading in certain instances to a suppression of proliferation (Lotan, Biochim. Biophys. Acta, 605:33-91, 1980) and in other instances to terminal differentiation of these cells, resulting in a more benign, non-neoplastic phenotype (see e.g., Brietman et al., Proc. Natl. Acad. Sci, U.S.A., 77:2936-2940, 1980).

retinoids

has been limited (Kamm et al., In: The Retinoids. Sporn et al., (eds.) Academic Press, N.Y., pp 228-326f 1984; Lippman et al., Cancer Treatment Reportsf 71:493-515,-1987). In-free form, the retinoids may have access to the surrounding normal tissues which might be the basis of their. . .

drug

distribution in vivo. This, in essence, involves attaining a high concentration and/or long duration of drug action at a target (e.g. a tumor) site where beneficial effects may occur, while maintaining a low concentration and/or reduced duration at other sites where adverse side effects may occur. . .

of the retinoid. The

retinoids may be administered parenterallyf topically, orally or intraperitoneally. The animal being administered the liposomes may bear a tumor impeded by retinoids and the administering step serve to impede growth of said tumor or the animal may have a dermatological disorderf ophthalmic diseasef rheumatic disease or vitamin deficiency responsive to retinoids wherein the administering step. . . In certain cases, the retinoid may be retinol, particularly all trans-retinol, The phospholipids of the present invention may be one or more of phosphatidylcholine, phosphatidylserine, phosphatidylglycerol, sphingomyelin and phosphatidic acid.

The processes of the present invention are particularly useful as a method for therapy or prophylaxis of an animal afflicted with cancer. Such a method may comprise: identifying'an animal afflicted with cancer; preparing liposomes comprising phospholipid and a retinoid; and parenterally administering a quantity of said liposomes to the animal, said quantity containing a therapeutically effective. . .

Such induced differentiation may be useful to impede proliferation of undifferentiated neoplastic cells or to promote the differentiation of normal cells having the potential differentiated capacity to attack neoplastic cells. More particularly as to the latter use, the liposome-encapsulated retinoids of the present invention may, for example, be used for inducing the. . .

dilauryloyl-

phosphatidylcholine, dipalmitoylphosphatidylcholine, distearoylphosphatidylcholine, 1-myristoyl palmitoyl- 4 phosphatidylcholine, 1-palmitoyl myristoyl phosphatidylcholine, 1-palmitoyl stearoyl phosphatidylcholine, 1-stearoyl palmitoyl phosphatidylcholinef dioleoylphosphatidylcholine, dilauryloylphosphatidylglycerol, dipalmitoylphosphatidylglycerol, distearoylphosphatidylglycerolr 5 dioleoylphosphatidylglycerol, dimyristoylphosphatidic acid, dipalmitoyl phosphatidic acid, dimyristoyl phosphatidylethanolamine, dipalmitoyl phosphatidylethanolamine, dimyristoyl phosphatidylserine, dipalmitoyl phosphatidylserine, brain phosphatidylserine,

10 brain sphingomyelin, dipalmitoyl sphingomyelin, and distearoyl sphingomyelin.

sites and thus circumvents the requirement for cell surface receptors. This may be of particular significance, for example, in therapy of tumors which lack the cell surface receptors for serum retinol binding protein but possess intracellular receptors for retinoic acid.

The use of vitamin A and its analogues (Retinoids) in the prevention and treatment of human cancer represents a relatively new direction in oncologic therapeutics.

Recent laboratory investigations have documented that the retinoids can block phenotypic expression of cancer, whether initiated by chemical, viral, physical, or biologic carcinogens. In humans also, the retinoids have been shown to cause regression of premalignant lesions.

of a protein cross-linking enzyme, tissue transglutaminase. Recent studies suggest that the inhibition of cystostatic activation is mediated through inhibition of secretion of tumor necrosis factor (TNF-alpha)-. In these studies, mouse peritoneal macrophages were activated in the presence of either intact serum or de-lipidized serum supplemented with retinoids. The cells were metabolically labeled with S-methionine. Immunoprecipitation with anti-TNF antibodies followed by SDS polyacrylamide gel electrophoresis showed, in addition to a major band at 170,5 Kd for TNF, the presence of high.

TGase may cause inter- or intra-molecular cross-linking of TNF, thereby inactivating it or inhibiting its secretion into the extracellular environment. Since factors such as tumor necrosis factor and interleukin-I (IL-1) (both are released by activated macrophages) are the main mediators of inflammation (Nawroth, et al., J. Exp..

retinoids may be effective in reversing UV-induced aging of the skin. Retinoids have also been used to treat rheumatic diseases, as immunomodulators (against cancer, infectious diseases, and parasitic diseases) as eye drops or ointments for preventing certain eye diseases, for treatment of vitamin A deficiency disorder, and.

#### EXAMPLE 5

In Vitro Inhibition of Tumor Cell Growth  
Liposomal all-trans retinoic acid (L-RA) was prepared as described in Example 1.

3H-thymidine was added to each culture and incorporation thereof into cellular polynucleotides measured. Table 4 shows the percentage of tumor growth inhibition as reflected by decreases in 3H-thymidine incorporation induced by L-RA of differing lipid compositions.

TABLE 4  
L-RA Inhibition of Tumor Cell Growth  
LIPOSOME COMPOSITION TUMOR CELL (THP-1)  
INHIBITION



DMPC:Cholesterol 72  
9:1  
DMPC:Cholesterol 22  
9:3  
DPPC 8  
DMPC;SA:Cholesterol 84  
8:1:1  
DMPC:DMPG 70  
7:3  
DMPC:DMPG 32  
9:1

From Table 4. it should be noted that L-RA (DMPC:DMPG-7:3). which, as previously shown hereinf gave a superior encapsulation efficiency and showed a low RBC toxicity (Tables 1 and 2)r also effectively inhibited the tumor cell growth.

THP-1 cells treated in vitro with RA (1 MM) for 72 hours when injected subcutaneously into male mice, failed to develop into tumors, whereas untreated cells formed a huge mass of tumors in such mice.

Human Peripheral Blood Monocytes  
by Intracellular Delivery of Retinoids  
Circulating blood monocytes are the precursors of macrophages which accumulate at the sites of tumor rejection [2], delayed hypersensitivity [25], chronic inflammation [6], and at the site of damaged tissue as a part of the healing processes [11]. . .

to macrophage-like cells  
was associated with the induction and accumulation of a specific intracellular TGasej tissue TGase (19,22]. Gamma (g)-interferon, which promotes the tumoricidal properties in HPBM, also augmented the expression of tissue TGase (19). Similarly the activation of guinea pig and mouse macrophages in vivo was. . .

gel and electro-  
blotted onto nitrocellulose paper. The paper was 5 neutralized with 5% bovine serum albumin and treated with iodinated anti-tissue TGase antibody; the preparation, characterization and propertie's of this antibody have been described elsewhere (24). The unbound antibody was removed by washing the paper in Tris-HCl buffer (50 mM pH 7.5) containing 200 mM NaCl. 5 mM EDTA, 0.5% Triton. . .

enzyme activity was  
caused by an increased amount of the enzyme peptide, as revealed by Western-blot analysis of cell lysates using a iodinated antibody to tissue TGase (Fig. 10B). The increase in enzyme activity was proportional to the increase in enzyme peptide and not caused by. . .

the subsets of HPBM isolated into small and large populations have been reported to produce different amounts of reactive-oxygen species [37], prostaglandins (1,30), antibody dependent cell-mediated cytotoxicity [27] and tumor-cell killing [26]. This functional heterogeneity among HPBM subpopulations has been attributed to either maturational or clonal differences.

Impairment of macrophage function in retinoid-deficient animals has been well documented to lead to

increased incidence-of infections and decreased tumor-cell killing (5]. In cultures of guinea pig peritoneal macrophages, RA has been reported to increase the intracellular levels for the tumoricidal enzyme arginase [32].

#### Do REFERENCES

20 lo Bankhurst A.D.r Hasteint E,r Goodwin, J.S., and Peake, J.E. The nature of the prostaglandin-producing mononuclear cells in human peripheral blood, J. Lab, Clin. Med. 97.179, 1981o  
25 2o Baum, M., and Fisher, S. Macrophage production by bone marrow of tumor bearing mice, Cancer Res, 32F2813r 1972o  
3e Cuatrecasasjr Po Hormone receptors, membrane phospho. Goodman, D.S., Eds.) New York: Academic Press, P. 373r 1984a  
6\* Dizont Q\*Sof and Southamf C.M. Abnormal cellular response to skin abrasions in cancer patients.

Cancer 16, 1288f 1963\*  
7\* Ferrero, D., Pressano, S., Pagliardi, G.L.r and Robera. G. Induction of differentiation of human myeloid leukemias: surface changes probed with monoclonal antibodies. Blood 61.171, 1983a  
8\* Ganguly, J., Roa, M.R.S., Murthy, S.K., and Sarada, K. Systemic mode of action of vitamin A. Vitam.

Cancer Res. 46,1388, 1986.

Cancer Res. 42,3924, 1982\*  
29\* Peterson, P.A. Characteristics of a vitamin A transporting protein complex occurring in human serum. J. Biol, Chem. 246,34, 1971.

Cancer Res. 43Y5707Y 1983\*  
39\* Yuspat S., Bent T.F and Steinert, P. Retinoic, acid induces transglutaminase activity but inhibits cornification of cultured epidermal cells.. . .

CLMEN. . . 1-myristoyl  
palmitoylphosphatidylcholine, 1-palmitoyl  
myristoyl phosphatidylcholine, 1-palmitoyl  
stearoyl phosphatidylcholine, 1-stearoyl palmitoyl  
phosphatidylcholine, -dioleoylphosphatidylcholine,  
dilauryloylphosphatidylglycerol, dipalmitoyl-  
phosphatidylglycerol, distearoylphosphatidylglycerol, dioleoylphosphatidylglycerol,  
dimyristoylphosphatidic acid, dipalmitoyl  
phosphatidic acid, dimyristoyl phosphatidylethanolamine, dipalm.-toyl phosphatidylethanolamine,  
dimyristoyl phosphatidylserine, dipalmitoyl  
phosphatidylserine, brain phosphatidylserine, brain  
sphingomyelin, dipalmitoyl sphingomyelin, and  
distearoyl sphingomyelin.

14 The method of claim 1 wherein the animal being  
25 administered the liposomes bears a tumor impeded by  
retinoids and the administering step serves to impede  
growth of said tumor.

20 A method for therapy of an animal afflicted with  
cancer-the method comprising:  
identifying an animal afflicted with cancer;

preparing liposomes comprising phospholipid and a  
retinoid; and

3 0

parenterally administering a quantity of said liposomes to the animal, said quantity containing a therapeutically effective amount of the retinoid.

21s A method for cancer chemotherapy of an animal, the method comprising:

identifying an animal afflicted with cancer  
preparing liposomes comprising phospholipid and retinoic acid; and

parenterally administering a quantity of said liposomes to the animal, said quantity containing a therapeutically effective amount of the retinoic acid.

36 The composition of claim 31 wherein the phospholipid is one or more of phosphatidylcholine, phosphatidylserine, phosphatidylglycerol, sphingomyelin, and phosphatidic acid.

=> d his

(FILE 'HOME' ENTERED AT 08:37:04 ON 07 AUG 2006)

FILE 'REGISTRY' ENTERED AT 08:37:14 ON 07 AUG 2006

E "BETA 2 GLYCOPROTEIN"/CN 25

E "APOLIPOPROTEIN"/CN 25

E "GLYCOPROTEIN 1"/CN 25

E "2-GLYCOPROTEIN 1"/CN 25

FILE 'MEDLINE' ENTERED AT 08:38:46 ON 07 AUG 2006

L1 89 S BETA-2-GLYCOPROTEIN-1  
L2 1833409 S CANCER? OR TUMOR? OR NEOPLAS?  
L3 0 S L2 AND L1

FILE 'PCTFULL' ENTERED AT 08:39:55 ON 07 AUG 2006

L4 59 S (BETA-2-GLYCOPROTEIN) OR (BETA 2 GLYCOPROTEIN)  
L5 8 S L4/AB  
L6 99855 S CANCER? OR TUMOR? OR NEOPLAS?  
L7 3 S L5 AND L6  
L8 123 S AMINOPHOSPHOLIPID?  
L9 3278 S PHOSPHATIDYL SERINE OR PHOSPHATIDYL ETH?  
L10 2328 S L9 AND L6  
L11 89879 S ANTIBOD?  
L12 1874 S L10 AND L11  
L13 0 S L6/CLM.  
L14 32790 S L6/CLM  
L15 874 S L14 AND L12  
L16 66 S L9/AB  
L17 15 S L16 AND L15  
L18 1 S L17 NOT PY>1998

=> s 18/clm

L19 10 (AMINOPHOSPHOLIPID?/CLM)

=> s 18/ab

L20 7 (AMINOPHOSPHOLIPID?/AB)

=> s 120 or 119

L21 13 L20 OR L19

=> s 121 and 111

L22 11 L21 AND L11

=> s l22 and l6

L23 10 L22 AND L6

=> s l23 not py>1998

776694 PY>1998

L24 0 L23 NOT PY>1998

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

33.64

36.00

STN INTERNATIONAL LOGOFF AT 08:51:02 ON 07 AUG 2006

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1642BJF

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS	4	APR 04	STN AnaVist \$500 visualization usage credit offered
NEWS	5	MAY 10	CA/CAPplus enhanced with 1900-1906 U.S. patent records
NEWS	6	MAY 11	KOREAPAT updates resume
NEWS	7	MAY 19	Derwent World Patents Index to be reloaded and enhanced
NEWS	8	MAY 30	IPC 8 Rolled-up Core codes added to CA/CAPplus and USPATFULL/USPAT2
NEWS	9	MAY 30	The F-Term thesaurus is now available in CA/CAPplus
NEWS	10	JUN 02	The first reclassification of IPC codes now complete in INPADOC
NEWS	11	JUN 26	TULSA/TULSA2 reloaded and enhanced with new search and and display fields
NEWS	12	JUN 28	Price changes in full-text patent databases EPFULL and PCTFULL
NEWS	13	JUL 11	CHEMSAFE reloaded and enhanced
NEWS	14	JUL 14	FSTA enhanced with Japanese patents
NEWS	15	JUL 19	Coverage of Research Disclosure reinstated in DWPI
NEWS	16	AUG 09	INSPEC enhanced with 1898-1968 archive

NEWS EXPRESS JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT  
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items  
NEWS IPC8 For general information regarding STN implementation of IPC 8  
NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 12:00:39 ON 16 AUG 2006

=> file pctfull

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'PCTFULL' ENTERED AT 12:00:53 ON 16 AUG 2006  
COPYRIGHT (C) 2006 Univentio

FILE LAST UPDATED: 14 AUG 2006 <20060814/UP>  
MOST RECENT UPDATE WEEK: 200632 <200632/EW>  
FILE COVERS 1978 TO DATE

>>> IMAGES ARE AVAILABLE ONLINE AND FOR EMAIL-PRINTS <<<

>>> NEW IPC8 DATA AND FUNCTIONALITY NOW AVAILABLE IN THIS FILE.

SEE

<http://www.stn-international.de/stndatabases/details/ipc-reform.html> >>>

>>> FOR CHANGES IN PCTFULL PLEASE SEE HELP CHANGE  
(last updated April 10, 2006) <<<

>>> NEW PRICES IN PCTFULL AS OF 01 JULY 2006. FOR DETAILS,  
PLEASE SEE HELP COST <<<

=> s prothrombin or kininogen? or prekallikrein

2523 PROTHROMBIN

35 PROTHROMBINS

2534 PROTHROMBIN

(PROTHROMBIN OR PROTHROMBINS)

617 KININOGEN?

232 PREKALLIKREIN

L1 3041 PROTHROMBIN OR KININOGEN? OR PREKALLIKREIN

=> s 11/ab

78 PROTHROMBIN/AB

1 PROTHROMBINS/AB

78 PROTHROMBIN/AB

((PROTHROMBIN OR PROTHROMBINS)/AB)

16 KININOGEN?/AB

2 PREKALLIKREIN/AB

L2 96 (PROTHROMBIN/AB OR KININOGEN?/AB OR PREKALLIKREIN/AB)

```
=> s cancer? or tumor? or neoplas?
      80623 CANCER?
      67255 TUMOR?
      23370 NEOPLAS?
L3      100308 CANCER? OR TUMOR? OR NEOPLAS?
```

```
=> s 13 and 12
L4      26 L3 AND L2
```

```
=> s antibod?
L5      90279 ANTIBOD?
```

```
=> s 14 and 15
L6      18 L4 AND L5
```

```
=> s treat?
L7      350797 TREAT?
```

```
=> s 17 and 16
L8      18 L7 AND L6
```

```
=> s 18 not py>1998
      781927 PY>1998
L9      5 L8 NOT PY>1998
```

```
=> d ibib 1-5
```

```
L9      ANSWER 1 OF 5      PCTFULL    COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER:      1998020118 PCTFULL    ED 20020514
TITLE (ENGLISH):      MODIFIED PROTEIN C AND METHODS OF USE THEREOF
TITLE (FRENCH):      PROTEINE C MODIFIEE ET PROCEDES D'UTILISATION
CORRESPONDANTS
INVENTOR(S):      ESMON, Charles, T.;
SMIRNOV, Mikhail
PATENT ASSIGNEE(S):      OKLAHOMA MEDICAL RESEARCH FOUNDATION
LANGUAGE OF PUBL.:      English
DOCUMENT TYPE:      Patent
PATENT INFORMATION:
      NUMBER      KIND      DATE
      -----
DESIGNATED STATES      WO 9820118      A1 19980514
      W:      AU CA JP AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL
PT SE
APPLICATION INFO.:      WO 1997-US20376      A 19971107
PRIORITY INFO.:      US 1996-8/745,254      19961108
US 1997-60/053,768      19970725
```

```
L9      ANSWER 2 OF 5      PCTFULL    COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER:      1992008479 PCTFULL    ED 20020513
TITLE (ENGLISH):      TISSUE FACTOR BASED PROTHROMBIN TIME REAGENT
TITLE (FRENCH):      REACTIF DE TEMPS DE PROTHROMBINE BASE SUR LA
THROMBOPLASTINE TISSULAIRE
INVENTOR(S):      BROWN, Scott, Martin
PATENT ASSIGNEE(S):      CORVAS INTERNATIONAL, INC.
LANGUAGE OF PUBL.:      English
DOCUMENT TYPE:      Patent
PATENT INFORMATION:
      NUMBER      KIND      DATE
      -----
DESIGNATED STATES      WO 9208479      A1 19920529
      W:      AT AU BE CA CH DE DK ES FI FR GB GR IT JP KR LU NL NO
SE
```

APPLICATION INFO.: WO 1991-US8174 A 19911104  
PRIORITY INFO.: US 1990-612,118 19901113  
US 1991-784,326 19911029

L9 ANSWER 3 OF 5 PCTFULL COPYRIGHT 2006 Univentio on STN  
ACCESSION NUMBER: 1991018992 PCTFULL ED 20020513  
TITLE (ENGLISH): METHODS TO MAKE AND USE PROTEINACEOUS MATERIAL PRESENT  
IN KININ-FREE HIGH MOLECULAR WEIGHT KININOGEN  
TITLE (FRENCH): PROCEDES DE FABRICATION ET D'UTILISATION DE MATIERE  
PROTEIQUE PRESENTE DANS LE KININOGENE DE MASSE  
MOLECULAIRE ELEVEE EXEMPT DE KININE  
INVENTOR(S): MOSHER, Deane, F.;  
ASAKURA, Shinji  
PATENT ASSIGNEE(S): WISCONSIN ALUMNI RESEARCH FOUNDATION  
LANGUAGE OF PUBL.: English  
DOCUMENT TYPE: Patent

PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9118992	A2	19911212

DESIGNATED STATES

W: AT AU BE CA CH DE DK ES FR GB GR IT JP LU NL SE  
APPLICATION INFO.: WO 1991-US3956 A 19910605  
PRIORITY INFO.: US 1990-544,133 19900608

L9 ANSWER 4 OF 5 PCTFULL COPYRIGHT 2006 Univentio on STN  
ACCESSION NUMBER: 1991006861 PCTFULL ED 20020513  
TITLE (ENGLISH): IMMUNOASSAYS FOR AND MONOCLONAL ANTIBODIES TO  
PROTHROMBIN ACTIVATION PEPTIDES AND THEIR DEGRADATION  
PRODUCTS  
TITLE (FRENCH): IMMUNOANALYSES DE DETECTION D'ANTICORPS MONOCLONAUX  
CONTRE LES PEPTIDES D'ACTIVATION DE PROTHROMBINE ET  
LEURS PRODUITS DE DEGRADATION  
INVENTOR(S): HURSTING, Marcie, J.;  
BUTMAN, Bryan, T.;  
STEINER, Jerald, P.;  
MOORE, Bryant, M.;  
DOMBROSE, Frederick, A.  
PATENT ASSIGNEE(S): AKZO N.V.;  
HURSTING, Marcie, J.  
LANGUAGE OF PUBL.: English  
DOCUMENT TYPE: Patent

PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9106861	A1	19910516

DESIGNATED STATES

W: AT AU BE CA CH DE DK ES FI FR GB GR IT JP KR LU NL SE  
APPLICATION INFO.: WO 1990-US6501 A 19901102  
PRIORITY INFO.: US 1989-431,964 19891106

L9 ANSWER 5 OF 5 PCTFULL COPYRIGHT 2006 Univentio on STN  
ACCESSION NUMBER: 1990015619 PCTFULL ED 20020513  
TITLE (ENGLISH): FACTOR Xa BASED ANTICOAGULANT COMPOSITIONS  
TITLE (FRENCH): COMPOSITIONS ANTICOAGULANTES A BASE DE FACTEUR Xa  
INVENTOR(S): ESMON, Charles, T.;  
TAYLOR, Fletcher, B., Jr.  
PATENT ASSIGNEE(S): OKLAHOMA MEDICAL RESEARCH FOUNDATION  
LANGUAGE OF PUBL.: English  
DOCUMENT TYPE: Patent

PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9015619	A1	19901227

DESIGNATED STATES

W: AT AU BE CA CH DE DK ES FR GB IT JP LU NL SE  
 APPLICATION INFO.: WO 1990-US3208 A 19900606  
 PRIORITY INFO.: US 1989-367,544 19890614

=> d kwic 2

L9 ANSWER 2 OF 5 PCTFULL COPYRIGHT 2006 Univentio on STN  
 ABEN Prothrombin time reagents are provided which comprise novel  
 liposome compositions in which  
 tissue factor is associated with and inserted into the. . .

DETD . . . and prothrombin). A second use is to  
 monitor patients undergoing long term oral anticoagulant  
 therapy for disorders such as recurrent venous thrombosis  
 and cancer (Hirsh, J., Seminars in Thrombosis and  
 Hemostasis, 12: 1-11, 1986) o A third use is to evaluate  
 liver dysfunction.

carrier protein and the detergent is then  
 removed. The detergent may be conveniently removed by  
 conventional methods, such as by dialysis, by resin  
 treatment or by dilution into a detergent-free solution.

Suitable methods of removal of detergent include dialysis,,  
 tangential flow diafiltration,, cross flow hollow fiber  
 filtration, treatment with hydrophobic chromatography  
 resin, and simple dilution.

as TBS containing 150 mM  
 trehalose,, 0.8% glycine and 0.05% NaN<sub>3</sub> to remove the  
 detergent. Another preferred method of detergent removal  
 utilizes resin treatment\* Suitable resins include  
 hydrophobic chromatographic resins such as Amberlite XAD-2  
 (Rohm and Haas Co. in Philadelphia,, Pennsylvania) or  
 Bio-Beads SM-2 (BioRad in Richmond, . . .

Another preferred method of detergent removal avoids  
 the use of either dialysis or resin treatment and yet  
 provides for preparation of active TF reagent, According  
 to this method, detergent solubilized phospholipids  
 containing TF are diluted into a buffer. . .

Examples

Example 1

Preparation of Anti-rTF Affinity Gel

The monoclonal antibody directed against TF, TF8-5G91  
 was obtained from Dr. T.S. Edgington and was made by the  
 procedure of Morrissey, J.H. et al., Thrombosis. . . . The TFS-509  
 ascites was purified to  
 IgG by DEAE chromatography using the procedure as  
 described in Harlow, E, and Lane,, D.,, Antibodies: A  
 Laboratory Manual, pp 304]305r Cold Spring Harbor  
 Laboratory (1988).

The immunoaffinity resin was prepared by covalent  
 attachment of the purified antibody to Affigel 10 (Biorad  
 Laboratories in Richmond,, California) by the procedure  
 recommended by the manufacturer. Thus,, 200 mg of  
 DEAE-purified monoclonal antibody was dialyzed into 0.1 M  
 MOPS (pH 7.5) to give a 10 mg/mL solution. 20 mL of this  
 antibody solution was then added to 20 mL of Affigel 10.



Triton concentration to 0.1% and then was passed through the immunoaffinity resin (made in Exam In pl-

1) containing a covalently coupled monoclonal antibody directed against TF. The resin bed was washed with 2 to 3 bed volumes of TBS + 0.1% Triton X100, 2 to. . .

Table III. Prothrombin Times with Control Plasmas Using Corvas rTF PT Reagent Prepared By XAD-2 Treatments  
Plasma Sample Average PT time in seconds  
Normal human plasma pool 12\*1  
Ortho Control Plasmas.

=> d kwic 3

L9 ANSWER 3 OF 5 PCTFULL COPYRIGHT 2006 Univentio on STN  
ABEN Disclosed herein are methods for using a proteinaceous material present in kinin-free high molecular weight kininogen to treat surfaces to prevent or minimize adhesion by blood components and/or animal cells. For example, in medical applications, one can treat plastic tubes or other conduits that carry blood to reduce the tendency of the blood to block the conduit. Also disclosed is an improved method of purifying kinin-free high molecular weight kininogen.

ABFR Procèdes d'utilisation d'une matière protéique présente dans un kininogène de masse moléculaire élevée exempt de kinine afin de traiter des surfaces de manière à empêcher ou à réduire au. . . afin de réduire la tendance du sang à bloquer le conduit. L'invention concerne également un procédé amélioré de purification de kininogène de masse moléculaire élevée exempt de kinine.

DETD In yet another aspect, surfaces treated with such proteinaceous materials are provided.

. . .  
cells to stick to them, and methods to more efficiently purify passifin. Another object is to provide surfaces (e.g. conduits) that have been treated in this manner. Still other objects and advantages of the present invention will be apparent from the description which follows. The following. . .

. . .  
1.0 M)  
prior to elution of histidine rich glycoprotein and antithrombin III. The desired fraction can be detected by immunoassays with anti-HMW kininogen antibodies, distinctive patterns in SDS PAGE, or anti-adhesive activity as described below.

. . .  
culture plates were precoated with vitronectin (a plasma protein which supports cell adhesion to the plates) (and/or a passifin/vitronectin mixture). Three types of tumor cells and one endothelial cell type were then spread on the plates. Cells did not spread on plates having the mixture, whereas. . .

. . .  
Ser Tyr Tyr Phe Asp Leu Thr Asp Gly  
615 620  
CUU` UCU -31 1911

Leu Ser

625

# Industrial Applicability

This invention may be useful in treating industrial pipes or surfaces to prevent clogging or sticking. It may also have utility to prevent clogging of medical equipment or perhaps even. . .

=> s glycoprotein I

20987 GLYCOPROTEIN

13580 GLYCOPROTEINS

27707 GLYCOPROTEIN

(GLYCOPROTEIN OR GLYCOPROTEINS)

876375 I

L10 486 GLYCOPROTEIN I

(GLYCOPROTEIN(W) I)

=> s 110/ab

882 GLYCOPROTEIN/AB

312 GLYCOPROTEINS/AB

1119 GLYCOPROTEIN/AB

((GLYCOPROTEIN OR GLYCOPROTEINS)/AB)

90468 I/AB

L11 13 (GLYCOPROTEIN I/AB)

((GLYCOPROTEIN(W) I)/AB)

=> d his

(FILE 'HOME' ENTERED AT 12:00:39 ON 16 AUG 2006)

FILE 'PCTFULL' ENTERED AT 12:00:53 ON 16 AUG 2006

L1 3041 S PROTHROMBIN OR KININOGEN? OR PREKALLIKREIN

L2 96 S L1/AB

L3 100308 S CANCER? OR TUMOR? OR NEOPLAS?

L4 26 S L3 AND L2

L5 90279 S ANTIBOD?

L6 18 S L4 AND L5

L7 350797 S TREAT?

L8 18 S L7 AND L6

L9 5 S L8 NOT PY>1998

L10 486 S GLYCOPROTEIN I

L11 13 S L10/AB

=> s 111 and 13

L12 3 L11 AND L3

=> d ibib 1-3

L12 ANSWER 1 OF 3

ACCESSION NUMBER:

TITLE (ENGLISH):

TITLE (FRENCH):

INVENTOR(S):

PATENT ASSIGNEE(S):

DOCUMENT TYPE:

PATENT INFORMATION:

PCTFULL COPYRIGHT 2006 Univentio on STN

2001018541 PCTFULL ED 20020828

USE OF BETA2GPI IN DIAGNOSTIC TESTS FOR AUTOIMMUNE DISEASES

UTILISATION DE LA PROTEINE &beta;2GPI DANS DES TESTS DIAGNOSTIQUES POUR LES MALADIES AUTO-IMMUNES

GECZY, Carolyn;  
MCNEIL, Hugh, Patrick;

VISVANATHAN, Sudha

PSIRON LIMITED;

GECZY, Carolyn;

MCNEIL, Hugh, Patrick;

VISVANATHAN, Sudha

Patent

	NUMBER	KIND	DATE
	WO 2001018541	A1	20010315
DESIGNATED STATES			
W:	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG		
APPLICATION INFO.:	WO 2000-AU1068	A	20000908
PRIORITY INFO.:	AU 1999-PQ 2726		19990909

L12 ANSWER 2 OF 3 PCTFULL COPYRIGHT 2006 Univentio on STN  
 ACCESSION NUMBER: 2001002017 PCTFULL ED 20020828  
 TITLE (ENGLISH): ERYTHROPOIETIN DERIVATIVES  
 TITLE (FRENCH): DERIVES DE L'ERYTHROPOIETINE  
 INVENTOR(S): BURG, Josef;  
 HILGER, Bernd;  
 JOSEL, Hans-Peter  
 PATENT ASSIGNEE(S): F. HOFFMANN-LA ROCHE AG  
 DOCUMENT TYPE: Patent  
 PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2001002017	A2	20010111
DESIGNATED STATES			
W:	AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG		
APPLICATION INFO.:	WO 2000-EP6009	A	20000628
PRIORITY INFO.:	US 1999-60/142,243		19990702
	US 1999-60/147,452		19990805
	US 1999-60/151,454		19990830

L12 ANSWER 3 OF 3 PCTFULL COPYRIGHT 2006 Univentio on STN  
 ACCESSION NUMBER: 1996004006 PCTFULL ED 20020514  
 TITLE (ENGLISH): USE OF AT LEAST ONE FORM OF THE 'beta'2-GLYCOPROTEIN I  
 AS AN ANTI-INFECTIOUS AGENT AND PHARMACEUTICAL  
 COMPOSITION CONTAINING SAME  
 TITLE (FRENCH): UTILISATION DE LA 'beta'2-GLYCOPROTEINE I SOUS AU MOINS  
 UNE DE SES FORMES COMME AGENT ANTI-INFECTIEUX ET  
 COMPOSITION PHARMACEUTIQUE CORRESPONDANTE  
 INVENTOR(S): STEFAS, Elie;  
 RUCHETON, Marcel;  
 GRAAFLAND, Hubert;  
 VEAS, Francisco  
 PATENT ASSIGNEE(S): INSTITUT FRANCAIS DE RECHERCHES SCIENTIFIQUES POUR LE  
 DEVELOPPEMENT EN COOPERATION- ORSTOM;  
 STEFAS, Elie;  
 RUCHETON, Marcel;  
 GRAAFLAND, Hubert;  
 VEAS, Francisco  
 LANGUAGE OF PUBL.: English  
 DOCUMENT TYPE: Patent  
 PATENT INFORMATION:

NUMBER	KIND	DATE
--------	------	------

-----  
WO 9604006                      A1 19960215  
DESIGNATED STATES  
W:                      JP US AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE  
APPLICATION INFO.:      WO 1995-FR1030              A 19950731  
PRIORITY INFO.:        FR 1994-94/09527              19940801

=> file his  
'HIS' IS NOT A VALID FILE NAME  
SESSION CONTINUES IN FILE 'PCTFULL'  
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files  
that are available. If you have requested multiple files, you can  
specify a corrected file name or you can enter "IGNORE" to continue  
accessing the remaining file names entered.

=> d his

(FILE 'HOME' ENTERED AT 12:00:39 ON 16 AUG 2006)

FILE 'PCTFULL' ENTERED AT 12:00:53 ON 16 AUG 2006

L1            3041 S PROTHROMBIN OR KININOGEN? OR PREKALLIKREIN  
L2            96 S L1/AB  
L3            100308 S CANCER? OR TUMOR? OR NEOPLAS?  
L4            26 S L3 AND L2  
L5            90279 S ANTIBOD?  
L6            18 S L4 AND L5  
L7            350797 S TREAT?  
L8            18 S L7 AND L6  
L9            5 S L8 NOT PY>1998  
L10           486 S GLYCOPROTEIN I  
L11           13 S L10/AB  
L12           3 S L11 AND L3

=> s l12 and l5  
L13           1 L12 AND L5

=> d ibib

L13    ANSWER 1 OF 1            PCTFULL    COPYRIGHT 2006 Univentio on STN  
ACCESSION NUMBER:            2001018541 PCTFULL    ED 20020828  
TITLE (ENGLISH):            USE OF BETA2GPI IN DIAGNOSTIC TESTS FOR AUTOIMMUNE  
DISEASES  
TITLE (FRENCH):            UTILISATION DE LA PROTEINE &beta;2GPI DANS DES TESTS  
DIAGNOSTIQUES POUR LES MALADIES AUTO-IMMUNES  
INVENTOR(S):            GECZY, Carolyn;  
                         MCNEIL, Hugh, Patrick;  
                         VISVANATHAN, Sudha  
PATENT ASSIGNEE(S):        PSIRON LIMITED;  
                         GECZY, Carolyn;  
                         MCNEIL, Hugh, Patrick;  
                         VISVANATHAN, Sudha  
DOCUMENT TYPE:            Patent  
PATENT INFORMATION:

NUMBER	KIND	DATE
-----		
WO 2001018541	A1	20010315

DESIGNATED STATES  
W:                      AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU  
CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN  
IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK  
MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM  
TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD  
SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY